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ABSTRACT 
Primary liver cancer (PLC) is the second most common cause of cancer death 
worldwide, preceded only by lung cancer. Current models for PLC either fail to fully 
recapitulate tumour histology and architecture or are expensive, time consuming and 
do not allow for personalised drug testing.  
During the first part of my PhD, I have collaborated with Dr. Laura Broutier in order to 
established a new 3D in vitro model system for liver cancer. Based on the current 
knowledge on organoid cultures, we have managed to establish a system to grow 
primary human liver cancer cells long-term (Broutier et al., in press). Interestingly, the 
tumour-derived organoids (tumoroids) recapitulate the original tumour histology and 
genetic alterations and are also able to generate tumours in an in vivo xenograft mouse 
model after long-term expansion. Furthermore, we have shown that tumoroids can also 
be successfully used for drug testing, suggesting their use to devise new targeted 
therapy as well as personalised treatment strategies.  
Current models to investigate the role of genes in cancer rely mostly on animal studies, 
which can be very time consuming and cost demanding, especially if resulting in 
negative outcomes. To overcome this issue, I have set up a protocol for introducing 
mutations in healthy human liver organoids using the CRISPR-Cas9 technology. 
Interestingly, after mutating TP53, RNF43 and ZNRF3 either alone or in combination, 
human organoids undergo genetic alterations and phenotypic changes that partially 
resemble the ones observed in tumoroids. This data suggests that this system could 
be used as a screening platform to study gene function before using animal models. 
In the last part, I have further explored the role of RNF43 and ZNRF3 (R&Z) - two newly 
identified WNT pathway negative regulators mutated in many cancer types - in the liver 
using an in vivo mouse model. Interestingly, conditional deletion of R&Z specifically in 
adult mouse hepatocytes results metabolic changes that eventually lead to extensive 
liver damage. However, when the liver is challenged to regenerate in a chronic damage 
model, R&Z mutated livers fail to fully repair and show presence of multiple 
regenerative nodules. Later, livers develop either focal nodular hyperplasia and/or 
early hepatocellular carcinoma. These data suggest that R&Z have an important role 
in both liver metabolic homeostasis and liver regeneration and that their alteration can 
eventually lead to cancer formation.  
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1. INTRODUCTION 
1.1 Liver anatomy 
The adult liver, the largest internal organ in the human body, performs a wide variety 
of functions ranging from metabolism and detoxification of harmful substances to 
protein synthesis and bile and urea production. The liver has two epithelial cell types, 
hepatocytes and cholangiocytes. The hepatocytes compose approximately 80% of the 
liver parenchyma and are responsible for most of its functions. Alternatively, 
cholangiocytes, or biliary duct cells, form the lining of the bile ducts. The role of the bile 
ducts is to collect and modify the bile produced by the hepatocytes and to transport it 
to the gallbladder for storage (Yoo, Lim, and Choi 2016).  
Structurally, the liver is organized into hepatic lobules which represent the structural 
and functional unit of the tissue (Figure 1.1a, b) (Gehart and Clevers 2015). At the 
centre of the hepatic lobule there is the central vein (CV). The area surrounding the 
CV, or perivenous area, is also defined as zone 3 (Figure 1.1a, b). Here, perivenous 
hepatocytes surround the CV and expand radially up to the portal triads in an ordered 
fashion to form a roughly hexagonal shape. Portal triads can be found at the edges of 
the hexagon, are composed by the portal vein (PV), hepatic artery and bile duct. The 
area surrounding the PV, or periportal area, is identified as zone 1 (Figure 1.1a, b). 
The bile ducts connect to the liver parenchyma through the canal of Hering, which is 
lined by both cholangiocytes and hepatocytes and it is where progenitor cells are 
thought to reside (Figure 1.1b) (Lukacs-Kornek and Lammert 2017). 
Of note, the liver lobule is also defined by distinct metabolic zonation with divergent 
hepatic function (Figure 1.1c) (Gebhardt 2014). For instance, gluconeogenesis and β-
oxidation are performed in the periportal area, whereas glycolysis and lipogenesis are 
carried out in the perivenous area. Hepatocytes within these regions also show unique 
gene expression patterns reflecting their diverse functions. The molecular basis of the 
metabolic zonation is not fully understood, however, the CV has been described as a 
source of WNT ligands (Gebhardt 2014). This CV secreted WNT causes expression of 
common WNT target genes such as Axin2, but also liver-specific ones, such as 
Glutamate Synthetase (GS – responsible for the synthesis of glutamine) and 
Cytochrome p450 (Cyp2e1 – involved in the metabolism of drugs and xenobiotics). In 
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the absence of WNT, Arginase1 (involved in the synthesis of urea) and Glutaminase2 
(involved in the hydrolysis of glutamine) are exclusively expressed in the periportal 
region (Benhamouche et al. 2006). 
 
Beyond the cell types described above the liver is home to many other resident cell 
types with independent roles (Figure 1.1b). These include macrophages, endothelial 
cells and stellate cells (Hindley, Cordero-Espinoza, and Huch 2016). Liver resident 
macrophages are also called Kupffer cells and can be usually found in the sinusoids, 
small blood vessels found widespread throughout the tissue. Endothelial cells form the 
lining of the blood vessels, including the sinusoids. Finally, hepatic stellate cells are 
pericytes involved in the scarring process of the tissue. 
	
Figure 1.1 Liver structure and zonation. a) Schematic representation of the hepatic lobule, with one 
central vein and six surroundings portal triads to from a hexagonal shape. PV, portal vein; CV, central 
vein. Adapted from (Duncan, Dorrell, and Grompe 2009). b) Magnification of the region between portal 
vein and central vein. The portal triad consists of bile duct, hepatic artery and portal vein that connect 
to the central vein through the sinusoids. The canal of Hering connect hepatocytes to duct cells and it 
is where progenitor cells are thought to reside. Sox9+ hepatocytes are found in the portal tract while 
Axin2+ hepatocytes are found in the central tract. Adapted from (Duncan, Dorrell, and Grompe 2009). 
c) Diagram showing difference in metabolic zonation of the liver and differential genes expression 
between periportal and perivenous area. Adapted from (Birchmeier 2016). 
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1.2 Liver regeneration 
The adult liver has a very slow turnover, especially when compared to actively dividing 
tissues, like the intestine. During homeostasis, average mammalian hepatocytes 
lifespan is estimated to be between 200 and 300 days (Bucher and Malt 1971). A 
recent report has shown that there is a defined population of hepatocytes, marked by 
the WNT target gene Axin2, which is responsible for hepatocytes turnover during 
homeostasis (B. Wang et al. 2015). The Axin2+ hepatocytes are diploid and located 
around the WNT rich CV region (Figure 1.1b) (B. Wang et al. 2015). Interestingly, these 
hepatocytes also express the pluripotency marker Tbx3 (T-Box3), expression that is 
then lost in the progeny of these cells. According to Wang et al., Axin2+ hepatocytes 
are able to replenish about 40% of the liver parenchyma in about 1 year in homeostasis 
conditions. However, it is important to consider how the lineage tracing experiments 
are performed in this work. The GFP allele used to trace the progeny of the Axin2+ 
hepatocytes are localised inside of the Axin2 allele itself, thus further validation is 
needed in order to assess that the expression of the gene is not altered by this 
modification, thus altering the results of the tracing experiment. Furthermore, the 
question still remains whether the progeny of these cells is able to replenish the whole 
liver parenchyma by itself or whether another source for hepatocytes, maybe in 
proximity of the portal area, exists. In line with this, a recent paper has shown that 
proliferative cells are not significantly localised around the pericentral area (Planas-
Paz et al. 2016), in contrast with the observation of Want et al.. Thus, it is indeed 
possible for other cells, other than Axin2+ hepatocytes, to be the source of newly 
formed liver cells during homeostasis.  
Mechanical injury or chemical and biological agents can alter the normal homeostatic 
equilibrium of the liver and lead to the activation of several regenerative responses. 
Several studies have demonstrated the enormous regenerative potential of the liver, 
being able to regenerate up to 70% of its mass following partial hepatectomy 
(Michalopoulos and DeFrances 1997). However, liver regeneration is a highly debated 
field and the scientific community is currently involved in understanding this complex 
mechanism. Considering the complexity of the regenerative process, tight regulation 
is essential to prevent liver failure and/or onset of liver diseases such as primary liver 
cancer. 
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Several mechanisms of liver regeneration have been suggested over the years and an 
overview can be found in Figure 1.2. Several studies have shown that, based on the 
type of damage model applied, both hepatocytes and cholangiocytes can be activated 
and can proliferate to compensate for the loss of either hepatocyte or cholangiocytes, 
respectively (Figure 1.2a) (Yanger et al. 2014; Lu et al. 2015).  Further studies have 
also shown that there is a population of hepatocytes located in the periportal area 
	
Figure 1.2. Overview of liver plasticity during regeneration in different models. a) Classic view of 
liver regeneration upon partial hepatectomy (HPx) or toxic injury. b, c, d) Alternative model for liver 
regeneration proposed for mouse, rat and human respectively. Regeneration is achieved by 
dedifferentiation to progenitor/oval cells and reprogramming to either hepatocytes or ductal cells. 
Adapted from (Hindley, Mastrogiovanni, and Huch 2014). 
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expressing both hepatocyte (HNF4α) and cholangiocyte (SOX9) markers - thus named 
hybrid hepatocytes – that accounts for about 5% of the hepatocyte population (Font-
Burgada et al. 2015). Interestingly, although these cells do not seem to contribute to 
damage repair after acute damage, they are able to replenish two-third of the entire 
liver parenchyma after mild chronic damage (Figure 1.1b) (Font-Burgada et al. 2015). 
Despite the vast regenerative potential of the hepatocyte compartment described 
above, it has been shown that cholangiocytes or progenitor cells of biliary origin can 
also be a potent source of regeneration, especially when hepatocytes proliferation is 
impaired (Figure 1.2) (Lu et al. 2015). Such a response, termed ductular reaction, is 
characterised by expansion of the ductal compartment. Moreover, it has been shown 
that upon treatment with the toxic agent carbon tetrachloride (CCl4), Lgr5+ (Leucine-
Rich Repeat-Containing G Protein-Coupled Receptor 5) cells arise from the ductal 
compartment and are able to generate both hepatocytes and cholangiocytes in the 
mouse liver (Huch, Dorrell, et al. 2013). CCl4 is a known toxic agent that induces death 
to the hepatocytes around the CV after being metabolized by the cytochrome p450 and 
have been extensively used to model liver damage in mouse models (Beer et al. 2008). 
Interestingly, Lgr5 was also found to be a stem cell marker in intestine, colon, stomach, 
hair follicle and other tissues (Barker et al. 2007, 2010; Jaks et al. 2008). Similar 
activation of Lgr5+ cells was also observed when damaging the liver using MCDE 
(methionine choline-deficient diet supplemented with ethionine) or DDC (3,5-
diethoxycarbonyl-1,4-dihydrocollidine) diet (Huch, Dorrell, et al. 2013). While the 
MCDE diet cause damage due to lack of two essential factors for the formation of 
phosphatidylcholine, thus altering very low density lipoprotein production, DDC causes 
the formation of porphyrin crystals within periportal hepatocytes and in small bile ducts 
(Delire, Stärkel, and Leclercq 2015). Both approaches and are known for triggering an 
oval cell response in the liver (Akhurst et al. 2001; Preisegger et al. 1999). Oval cells 
are bipotential transit amplifying cells thought to arise from progenitor cells residing in 
the canal of Hering and also capable of generating both hepatocytes and 
cholangiocytes (Figure 1.1b and Figure 1.2b, c, d) (Fausto and Campbell 2003).  
Finally, a novel player in liver regeneration has been recently identified in the rat liver. 
After partial hepatectomy, hepatic stellate cells have been shown to be able to undergo 
dedifferentiation, regeneration is then driven by re-differentiation of these cells into 
both hepatocytes and cholangiocytes (Figure 1.2c) (Kordes et al. 2014). Here, 
experiments were performed by transplanting fluorescently labelled stellate cells from 
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the bone marrow to the liver, and contribution to regeneration was assessed by 
analysis of the fluorescent progeny (Kordes et al. 2014). Due to the nature of this 
system it is still not possible to rule out a contribution of resident hepatic stellate cells 
to liver regeneration. Mouse hepatic stellate cells have also been suggested to give 
rise to hepatocytes after damage by employing Glial Fibrous Acidic Protein (GFAP) -
Cre lineage tracing (L. Yang et al. 2008). However, further studies have revealed that 
GFAP it is not specifically expressed in hepatic stellate cells but also in bile duct cells, 
thus invalidating the result of Yang et al. (Mederacke et al. 2013). Furthermore, by 
generating a hepatic stellate cells specific Cre line, Mederacke et al. also found no 
contribution of these cells to liver regeneration after several types of damage models 
(Mederacke et al. 2013).  
Taken together, all these data show how difficult as been trying to understand liver 
regeneration over the years. However, it is clear that the liver is a highly plastic organ 
capable of regenerating after several types of insults using distinct mechanisms. Also, 
the adult liver seems to not be relying on a well-defined stem cell compartment, but 
rather on the ability of mature cell types to proliferate and/or dedifferentiate to replenish 
and repair the organ. The question still remains whether other, still unknown, cells 
could be involved in the regenerative program of the liver (Figure 1.2b, c, d). 
 
1.3 Primary Liver Cancer 
Primary liver cancer (PLC) is the second most common cause of cancer death  
worldwide, preceded only by lung cancer (Siegel et al.; Bosch et al. 2004). The vast 
majority of adult liver cancers are split between two cancer types, hepatocellular 
carcinoma (HCC) and cholangiocarcinoma (CC). HCC and CC are both 
morphologically and genetically distinct malignancies. HCC is a solid tumour that 
grows in the liver parenchyma, it presents a hepatocyte-like phenotype and it is the 
most common type of PLC, representing 85-90% of them (El-Serag and Rudolph 
2007). CC arises from the lining of the bile duct and is characterized by a large stromal 
reaction. This tumour type can form from the bile duct located either inside or outside 
of the liver, with the intrahepatic CC accounting for 5-10% of PLCs (Guglielmi et al. 
2009). A third tumour type, that accounts for 0.5-5% of all PLCs, harbours intermediate 
features of both HCC and CC, thus called combined HCC/CC (CHC), and it is the 
rarest but also the most aggressive kind of PLC (Maximin et al. 2014; Moeini et al. 
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2017). Importantly, incidence and mortality have been increasing for both HCC and 
CC in the last ten years. 
PLCs are often associated to liver cirrhosis, representing the major risk factor for this 
disease, with or without hepatitis B or C infection, liver diseases and alcoholic and non-
alcoholic fatty liver disease (El-Serag and Rudolph 2007; Khan et al. 2005). Although 
these risk factors are shared among all PLCs, especially HCC and CHC, only a small 
percentage of CCs is known to arise as a consequence of chronic liver damage/ 
cirrhotic background due to hepatitis C or B infection (Pinter et al. 2016). On the other 
hand, parasitic infections, primary sclerosing cholangitis, biliary-duct cysts and toxins 
seem to play a greater role in the establishment of CC, with differences between intra- 
or extra-hepatic tumours (Tyson and El-Serag 2011). Although related to different 
etiological agents, both HCC and CC are linked to chronic liver damage. The 
persistence of chronic diseases and constant tissue and cell damage results in 
increased cell turnover, favouring the chances of errors during the repair process. 
These errors can lead to fibrosis and eventually to development of cirrhosis. In this 
setting, tumours can arise and proliferate (Figure 1.3a), while advanced tumours can 
metastasise to other tissues, with the lungs representing the primary metastatic site for 
PLCs (Marquardt, Andersen, and Thorgeirsson 2015). 
 
1.3.1 Non-alcoholic fatty liver disease and HCC 
As previously mentioned, non-alcoholic fatty liver disease (NAFLD) is one of the risk 
factors for the establishment of PLC, especially HCC. NAFLD is the most common liver 
disease, affecting between 25 to 35% of people in Europe and United States 
(Bellentani 2017). The disease is established when fat is accumulated in the liver, a 
condition defined as hepatic steatosis. Steatosis has been considered to be not 
pathological relevant for years, however, an increase amount of fat in the tissue is now 
known to trigger an inflammatory response, causing cell damage and, in some cases, 
leading to non-alcoholic steatohepatitis (NASH), the most aggressive form of the 
disease (Lonardo et al. 2017). Fat accumulation and the subsequent damage to the 
tissue, due to reactive oxygen species and excessive inflammatory response, can 
promote liver fibrosis and, in about 10-15% of the cases, cirrhosis and eventually PLC 
(White, Kanwal, and El–Serag 2012). Although cirrhosis is a major risk factor for HCC, 
recent studies have revealed that in 45% of the cases HCC can also arise in patients 
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affected by NAFLD without a cirrhotic liver, although with a less aggressive phenotype 
(Piscaglia et al. 2016). However, the molecular events that link NAFLD to HCC are still 
not understood. Common risk factors for NAFLD are obesity, type 2 diabetes mellitus 
and insulin resistance and it is often also related to metabolic syndrome. The disease 
is usually asymptomatic until cirrhosis is developed and mortality is caused either by 
the consequent cardiovascular disease or establishment of HCC, which represent the 
second most common complication of NAFLD (Masuzaki, Karp, and Omata 2016). Due 
to the increasing incidence of both NAFLD and HCC, further studies on the link 
between the two diseases are necessary in order to shed a light of the molecular 
mechanisms underlying the establishment of NAFLD/HCC. 
 
1.3.2 Origin of PLCs 
There is still heavy debate surrounding the origin of the PLC subtypes. Due to the 
histological features of the specific tumour types, mature hepatocytes were originally 
thought to be the main cell type of origin for HCC, whereas the intrahepatic bile duct 
epithelium would give rise mainly to CC (El-Serag and Rudolph 2007; Sia et al. 2013). 
Also, progenitor cells are thought to be the cells of origin for CHC (Figure 1.3b, c). 
However, more recently there have been reports stating that the situation might not be 
that simple and that based on the differentiation status of the transformed cell, 
hepatocytes and cholangiocytes could also both be the source for CHC and 
hepatocytes could also be the where CC originate from (Marquardt, Andersen, and 
Thorgeirsson 2015). Also, this theory includes the possibility for all tumour types to 
arise from a progenitor or a stem cell (Marquardt, Andersen, and Thorgeirsson 2015). 
In support of this hypothesis, many murine liver cancer models have been generated 
introducing mutations in the liver bipotent progenitor hepatoblasts - and 
consequentially in hepatocyte and cholangiocytes - leading to formation of either HCC 
or CC. These data suggest that the specific mutation introduced can actually drive 
formation of a tumour type instead of the other and further support the hypothesis of 
the importance of the differentiation status of the mutated cells (Saha et al. 2014; 
Zender et al. 2013; Nantasanti et al. 2016). For instance, mice constitutively 
overexpressing the intracellular domain of the Notch receptor (NICD) in albumin-
expressing cells - thus presenting the over-expression of NICD in both hepatocytes 
and cholangiocytes - results in CC development during adulthood (Zender et al. 2013). 
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Similarly, when Tp53 and Rb (Retinoblastoma protein) are mutated instead, HCC, but 
not CC, is formed after that the liver is challenged to regenerate (Nantasanti et al. 
2016). Of note, when both NOTCH and AKT signalling are activated together in 
hepatocytes, cells are induced to trans-differentiate to a bile duct lineage and then give 
rise to CC (Fan et al. 2012). Thus, hepatocytes can give rise to CC by first 
transdifferentiating to cholangiocytes. 
This new view reflects very well the concept of plasticity during regeneration, where 
cells can dedifferentiate to repopulate other compartments in the liver. In line with this, 
reprograming errors, mutations and/or cell damage can lead to the establishment of a 
tumour type that differ from the original mature cell. 
 
 
	
Figure 1.3 Origin and progression of liver cancer. a) Evolution of liver cancer from cirrhosis to 
establishment of a primary liver tumour and metastasis to the lungs. b, c) Schematic representations of 
the cell of origin of the different tumour types. Upon damage, mutated cells can acquire transformed 
phenotype and promote cancer formation. Specifically, ductal cells give CC and CHC, and hepatocytes 
and progenitor cells give both CC, HCC and also CHC. Adapted from (Marquardt, Andersen, and 
Thorgeirsson 2015). 
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1.3.3 Therapies for PLCs 
Considering the heterogeneity of PLCs, it is very difficult to devise a common 
therapeutic strategy that would be effective for all tumours. For this reason, each case 
has to be assessed individually. Current therapies for PLC rely mainly on surgical 
resection, when possible and/or when liver function is preserved, or on the use of 
chemotherapy and/or local radiotherapy (Pinter et al. 2016). The gold standard therapy 
for PLCs is transarterial chemoembolization (TACE) where a blocking material mixed 
with a chemotherapy drugs is injected into the hepatic artery to block the blood supply 
of the tumour (Best et al. 2016). Alternatively, in cases where liver function is severely 
impaired, liver transplantation is also considered, especially to treat HCC. Recently, 
targeted therapy using the multi-kinase inhibitor Sorafenib has been used to treat 
advanced HCC  resulting in extended survival rate when compared to patients treated 
with placebo (Llovet et al. 2008). Sorafenib has been shown to act not only on kinases 
involved in proliferation stimuli and survival (KRAS, BRAF), but also in inhibiting the 
promotion of vascularization by acting on VEGFR (vascular endothelial growth factor 
receptor) 2 and 3 (Wilhelm et al. 2004). To date Sorafenib is the only drug that has 
shown therapeutic potential in treating HCC. The success in using Sorafenib as 
targeted therapy for HCC has highlighted how important it is to understand tumour 
biology and genetics, to allow for better drug screening and to selectively target specific 
deregulated pathways. 
 
1.4 Genetics of PLCs 
Due to the higher incidence of HCC over CC, efforts aimed at elucidating the mutational 
spectra of PLCs have mainly been focused on HCC (Guichard et al. 2012; Fujimoto et 
al. 2012). However, due to a considerable increase of CC incidence (more than 100%) 
in the last three decades (Shaib et al. 2004), many studies have been recently made 
in order to also characterise the genetic background of CC (Jiao et al. 2013; Ong et al. 
2012; Zou et al. 2014). These studies have unrevealed the mutational landscape of 
both HCC and CC (Table 1.1).  
The key regulatory genes and pathways mutated in PLCs comprise several known 
oncogenes and tumour suppressor genes, as well as newly identified chromatin 
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remodelling (CR) genes involved in cancer (Guichard et al. 2012; Fujimoto et al. 2012; 
Jiao et al. 2013). Alteration of the Tumour Protein p53 (TP53)/cell cycle pathway seems 
to play a crucial role in both HCC and CC, as mutations in TP53 have a frequency of 
20.8% and 38.2%, respectively (Guichard et al. 2012; Zou et al. 2014). In line with this, 
TP53 mutations have also been frequently found in CHC (~27%), where only few 
studies have been carried out so far due its rarity (Maximin et al. 2014). Recently, 
TERT promoter mutations have been found very frequently in HCC (60%) suggesting 
that this could be an early step in the tumorigenesis process (J.-C. Nault and Zucman-
Rossi 2016). In CC, the most common mutated gene is TP53 followed by alterations 
of Kirsten rat sarcoma viral oncogene homolog (KRAS) (16.7%) (Zou et al. 2014). Of 
note, KRAS is not very commonly mutated in HCC (1.6%) (Guichard et al. 2012). On 
the other hand, mutations in the Wingless/Integrated (WNT) signalling pathway 
proteins have mainly been detected in HCC, where β-catenin (CTNNB1) is mutated in 
32.8% of the cases (Guichard et al. 2012).  
Table 1.1. Incidence of mutations in HCC and CC tumours. 
Gene Role Incidence in HCC Incidence in CC 
TERT Immortalization 60% (Schulze et al. 2015) - 
TP53 Cell cycle/apoptosis 20.8% (Guichard et al. 2012) 38.2% (Zou et al. 2014) 
RB1 Cell cycle/apoptosis 4% (Schulze et al. 2015) 5% (Zou et al. 2014) 
SMAD4 Cell cycle/apoptosis - 16.7% (Ong et al. 2012) 
PEG3 Cell cycle/apoptosis - 5.6% (Ong et al. 2012) 
IRF2 Cell cycle/apoptosis 4.8% (Guichard et al. 2012) - 
KRAS G protein signalling 1.6% (Guichard et al. 2012) 16.7% (Ong et al. 2012) 
PTEN G protein signalling 3% (Schulze et al. 2015) 6% (Zou et al. 2014) 
ROBO2 G protein signalling - 9.3% (Ong et al. 2012) 
IDH1 Chromatin remodelling - 5% (Zou et al. 2014) 
ARID1A Chromatin remodelling 16.8% (Guichard et al. 2012) 6.9% (Zou et al. 2014) 
ARID1B Chromatin remodelling 6.7% (Fujimoto et al. 2012) - 
ARID2 Chromatin remodelling 5.6% (Guichard et al. 2012) - 
MLL3 Chromatin remodelling 4.2% (Fujimoto et al. 2012) 14.8% (Ong et al. 2012) 
MLL Chromatin remodelling 1.7% (Fujimoto et al. 2012) - 
BPTF Chromatin remodelling 1.7% (Fujimoto et al. 2012) - 
CTNNB1 WNT signalling 32.8% (Guichard et al. 2012) - 
AXIN1 WNT signalling 15.2% (Guichard et al. 2012) - 
APC WNT signalling 1.6% (Guichard et al. 2012) - 
ZNRF3 WNT signalling 3% (Schulze et al. 2015) - 
RNF43 WNT signalling - 9.3% (Ong et al. 2012) 
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Interestingly, CTNNB1 and TP53 mutations are mutually exclusive, but mutations of 
TP53 and the WNT signalling genes Axis inhibitor 1 (AXIN1) (15.2%) and 
Adenomatous Polyposis Coli (APC) (1.6%) are not (Guichard et al. 2012). In addition, 
mutations of Zinc finger 3 (ZNRF3) are also found in HCC at a frequency of 3% 
(Schulze et al. 2015). ZNRF3 and Ring Finger 43 (RNF43) are two homologous 
proteins recently found to be negative regulators of the WNT pathway in the mouse 
intestine (Koo et al. 2012). Interestingly, mutations in RNF43 (9.3%) can only be found 
in CC, making this gene the first WNT pathway-relate gene to be mutated in CC 
identified thus far (Ong et al. 2012).  
An interesting similarity between the two tumour types, is the high prevalence of 
mutations in the chromatin regulator gene AT-rich interaction domain protein 1 A 
(ARID1A) (16.8% in HCC and 6.9% in CC), that again shows mutual exclusivity with 
TP53 mutations (Guichard et al. 2012; Zou et al. 2014). Mutations in other CR genes 
have also been reported for both cancer types and are listed in Table 1.1. Interestingly, 
although some of the mutations found in CR genes are mutually exclusive, 50% of the 
tumour samples presented at least one mutation in one of these genes. Therefore, 
considering the high frequency of mutations in the aforementioned genes, it is 
reasonable to think that TP53, WNT signalling pathway and CR genes could play a 
critical role in the initiation and progression of liver cancers.  
 
1.4.1 TP53, the guardian of the genome 
The high incidence of TP53 mutations in both HCC and CC suggests that inactivation 
of the gene is potentially one of the initial steps of liver tumorigenesis. TP53 exerts 
important roles in both normal and cancerous liver (Meng et al. 2014). Specifically, 
DNA damage and stress stimuli leads to TP53 activation that in turn promotes cell 
cycle arrest and/or apoptosis (Meng et al. 2014). TP53 is also important in maintaining 
the normal number of chromosomes during mitosis. This is especially evident in the 
liver as hepatocytes show a higher “ploidy” when TP53 is inactivated (Kurinna et al. 
2013). More recently, another role for TP53 in tumour prevention has been suggested. 
TP53 competent hepatic stellate cells would contribute to the formation of a tumour-
preventing microenvironment, inhibiting malignant transformation of neighbour cells by 
recruiting macrophages to supress the proliferation or survival of pre-malignant cells 
(Lujambio et al. 2013; Chua, Chan, and Tang 2014). Therefore, activation of TP53 is 
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essential to prevent a tumorigenic state (Vassilev et al. 2004). In addition, TP53 has 
also been used as target to induce apoptosis in cancer cells harbouring wilt-type copies 
of the gene. In line with this, the small molecule Nutlin3 is able to induce TP53 
activation by blocking its interaction with the inhibitor MDM2 (Mouse double minute 
homologue 2) (Schug 2009; Hardcastle 2007). However, the use of this drug to target 
tumours with wild-type copies of TP53 is limited by the possibility of also not cancerous 
cells to be affected. 
 
 
1.4.2 The ARID family protein 
ARID1A, commonly mutated in both HCC and CC, is a member of the chromatin 
remodelling SWI/SNF (SWItch/Sucrose Non Fermentable) complexes (Helming, 
Wang, and Roberts 2014; Reisman, Glaros, and Thompson 2009). There are two main 
complexes in this family, the BAF (BRG1-associated factor) complex and the PBAF 
(Polybromo-associated BAF) complex. These two complexes differ in protein 
composition and crucially include different members of the ARID protein family. 
ARID1A and ARID family protein in general play a crucial role in the proper functioning 
of the SWI/SNF complexes as the ARID domain confers the ability to bind DNA in a 
non-specific fashion, thus allowing the complex to exert its role. Some of these 
functions include promotion of nucleosome remodelling and regulation of many 
biological processes including proliferation, differentiation, apoptosis and DNA repair. 
Mutations in the ARID family members have been initially reported in ovarian clear cell 
carcinoma and ovarian endometroid carcinoma, whereby ARID1A is mutated in 50% 
and 30% of the cases, respectively (Wiegand et al. 2010; Jones et al. 2010). 
Subsequently, comprehensive studies have uncovered mutations for these genes in 
gastric and colorectal cancer (Cajuso et al. 2014).  In liver cancer, mutations for 
	
Figure 1.4. Nutlin3 mediated activation of TP53. In homeostatic conditions, MDM2 binds to TP53 to 
prevent activation of TP53-target genes. Nutlin3 prevents the interaction between MDM2 and TP53, 
allowing TP53 to activate its target genes and promote senescence, apoptosis and/or cell cycle arrest	
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ARID1A have been described for both HCC and CC, whereas ARID1B and ARID2 
mutations have only been described in cases of HCC (Schulze et al. 2015). ARID1A 
and ARID2 have been suggested to have tumour suppressor role in many tissues, 
whereas the role of ARID1B in cancer is still unclear(J. N. Wu and Roberts 2013; Zhao 
et al. 2011). Of note, ARID1A mutations were more prevalent in tumours related to 
alcohol intake rather than hepatitis B or C infections, whereas ARID2 mutations were 
not significantly associated with any of the risk factor analysed (Guichard et al. 2012). 
No data for ARID1B mutations is available yet. 
Interestingly, a recent report has shown that ARID1B expression is essential for 
survival of ARID1A-deficient cell lines, suggesting a dependence of ARID1A-deficient 
tumours on ARID1B and highlighting the possibility of using this vulnerability to treat 
these specific cancer types (Helming et al. 2014). On the same line, pharmacological 
inhibition of the DNA damage checkpoint kinase ATR (Ataxia Telangiectasia And 
Rad3-Related Protein) or of the methyltransferase EZH2 (Enhancer of Zeste Homolog 
2) has been shown to be lethal for cancer cells harbouring ARID1A mutations both in 
vitro and in vivo (Bitler et al. 2015; Williamson et al. 2016). 
 
1.4.3 The canonical WNT signalling pathway 
The WNT signalling pathway has many important roles, ranging from cell fate decision 
during embryogenesis to regulation of tissue homeostasis in many adult tissues 
(Clevers and Nusse 2012). For this reason, it is not surprising that mutations in 
components of this pathway are observed in tumours originating from a number of 
tissues, including colon, pancreas, breast, skin and others (Wend et al. 2010). In the 
liver, members of the canonical WNT signalling pathway are frequently mutated in 
HCC, whereas only RNF43 has been found mutated in CC so far (Guichard et al. 2012; 
Ong et al. 2012). 
The WNT signalling pathway starts when the ligand, WNT, binds to the receptor 
complex composed of Frizzled and its co-receptors LRP5/6 (Low Density Lipoprotein 
Receptor-Related Protein) the WNT pathway is activated (Figure 1.5a, b). This 
interaction leads to the inhibition of a complex of protein called the destruction complex, 
which in turn allows the effector protein β-catenin to accumulate in the cytoplasm first 
and then translocate into the nucleus (Figure 1.5b). The destruction complex is 
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composed by several proteins with structural purpose, such as APC and AXIN1, and 
kinases that mediate recognition and degradation of β-catenin by the proteasome, 
such as GSK3β (glycogen synthase kinase 3 beta) and CK1 (casein kinase 1) (Figure 
1.5a, b). When in the nucleus, β-catenin can associate to the transcription factors 
LEF/TCF (lymphoid enhancer factor/ T-cell factor) and promote transcription of WNT 
responsive genes (Figure 1.5b) (Clevers and Nusse 2012). When WNT is not present, 
the pathway is inactive and β-catenin is targeted for degradation by the destruction 
complex (Figure 1.5a). Of note, loss of function mutations in members of the 
destruction complex, like Apc or Axin, result in constant activation of the pathway even 
in the absence of the ligand (Sansom et al. 2004). Similarly, mutations that prevent 
correct ubiquitination of β-catenin by the destruction complex also leads to WNT 
independent activation of the pathway and can lead to tumour formation (Dong et al. 
2015).  
 
 
Figure 1.5. The WNT signalling pathway. a) In the absence of the ligand, WNT, the pathway is not 
active and β-catenin is degraded after being targeted by the destruction complex. b) When WNT is 
present, it binds to Frizzled and LRP preventing the formation of the destruction complex and allowing 
β-catenin to translocate into the nucleus and drive expression of WNT responsive genes. c) Activation 
of the pathway leads to the expressing and localization of the two homologous E3 ubiquitin ligases 
RNF43 and ZNRF3 on the cell surface. These proteins induce internalization and ubiquitination of 
Frizzled, thus negative regulating the WNT pathway. d) However, when the WNT agonist RSPO1 is 
present, it mediates the binding of RNF43 and ZNRF3 to LGR5, which leads to the internalization of this 
newly formed complex, thus positively regulating the pathway. Adapted from (Yu and Virshup 2014). 
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The destruction complex is not the only way in which the WNT pathway is regulated. 
Secreted molecules, like the Dickkopf proteins (Dkks) and the secreted Frizzled-
related proteins (sFRPs), are able to bind to Frizzled and/or LRP5/6 and prevent 
ligand-receptor interaction (Cruciat and Niehrs 2013). More recently, new players 
involved in regulating the pathway at the receptor level have been identified, namely 
RNF43 and ZNRF3 (R&Z), two homologous E3 ubiquitin ligases (Koo et al. 2012). R&Z 
are expressed on the cell surface after activation of the WNT pathway (Figure 1.5b, c). 
They are single-pass transmembrane proteins with an extracellular PA domain and a 
cytoplasmic RING domain, that allow substrate-specific recognition for ubiquitination 
(de Lau et al. 2014) (Figure 1.6). When expressed on the cell surface, R&Z regulate 
the WNT pathway in a negative-feedback loop manner by promoting internalization 
and degradation of Frizzled, in a ubiquitination-dependent manner (Figure 1.5c) (Hao 
et al. 2012). Positive regulation of the pathway is instead achieved when the secreted 
molecule R-spondin1 (RSPO1) binds to both LGR4/5 and R&Z. The complex is then 
removed from the cell membrane and R&Z are no longer able to inhibit the pathway 
(Figure 1.5d) (Yu and Virshup 2014). Thus, RSPO1 acts as a positive regulator of the 
WNT pathway. Of note, LGR4/5 are also WNT targets, thus they are expressed when 
the pathway is activated. 
 
Of note, ablation of both RNF43 and ZNRF3 in the mouse intestine induces rapid 
formation of adenomas with enlargement of the stem cell compartment, suggesting 
R&Z as another fragile regulatory effector of the WNT signalling pathway (Koo et al. 
2012). Interestingly, R&Z intestinal tumours have been found to rely on their paracrine 
WNT source, the Paneth cells. Indeed, blocking of WNT secretion by porcupine 
inhibition has shown to strongly inhibit tumour growth in vivo without affecting normal 
crypts homeostasis (Koo et al. 2015). More recently, a new study has shown how 
	
Figure 1.6. Schematic representation of RNF43 and ZNRF3 domains. RNF43 and ZNRF3 share the 
same structural and functional domains, including the extracellular PA domain and the cytoplasmic 
RING domain. TM, transmembrane domain. Adapted from (Koo et al. 2012). 
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RNF43 and ZNRF3 could also have an important role also in the mouse liver by 
regulating metabolic zonation (Planas-Paz et al. 2016). Specifically, whole body R&Z 
deletion (using Rosa-CreERT2 allele) results in increased staining for GS and 
CYP2E1, two liver-specific WNT target genes involved in metabolism and localised 
around the CV. In addition, Planas-Paz et al. have also observed a 10% increase in 
proliferation 10 days after the deletion had been performed. Opposite results were 
instead observed when performing deletion of LGR4/5, thus confirming an opposite 
role for R&Z and LGR4/5 in regulating the WNT pathway. Despite the interesting 
results, further studies are needed to fully understand the consequence of R&Z 
deletion specifically in the liver. 
After the identification of RNF43 as tumour suppressor, frequent inactivating mutations 
have been observed in many tumour types of pancreas, stomach and endometrium (J. 
Wu et al. 2011; Furukawa et al. 2011; K. Wang et al. 2014; Giannakis et al. 2014). 
Similarly, mutations in ZNRF3 have been detected in a number of tumours, albeit less 
frequently (Wolpin et al. 2014; Zhou et al. 2013; Juhlin et al. 2014). In the liver, RNF43 
mutations have been identified mainly in liver fluke-associated CC (~9.3%) (Ong et al. 
2012; Jusakul, Kongpetch, and Teh 2015). Interestingly, a more recent report 
correlates RNF43 mutations with poor prognosis between patients with CC and also 
suggests a possible role for RNF43 in the development of this pathology (Talabnin et 
al. 2016). On the contrary, ZNRF3 has been found mutated only in HCC (~3%) in a 
cohort study where 243 liver tumours were analysed (Schulze et al. 2015).  
 
1.5 Liver cancer modelling 
In order to better understand PLCs and to devise better therapies, many cancer models 
have been generated and used over the years (He et al. 2015; Heindryckx, Colle, and 
Van Vlierberghe 2009). The use of cell lines has allowed pioneering studies and 
preliminary drug testing. Animal models have proven to be essential to understand the 
genetic mechanisms underlying tumour initiation and progression. Also, the use of 
animal models has enabled the possibility for the development of new cancer 
treatments. However, considering the histological and genetic complexity of PLCs, it 
has become clearer that each case of the disease is unique and needs precise and 
personalised treatment. As a result, there is a growing need of new PLC models that 
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will also allow for personalized drug testing. Pros and cons of the different model 
systems are listed in Table 1.2. 
 Table 1.2. Pros and cons of cancer modelling strategies. 
Model system Pros Cons 
Cell lines 
- Inexpensive to maintain 
- Easy to use for multiple applications 
- Bulk use for drug testing 
- Provide reproducible results 
- Can form spheroids 
- Difficult to derive 
- Do not model microenvironment 
- Do not recapitulate histology 
- Frequent mutations at higher 
passages 
Chemically-
induced tumour 
- Tumours in 6 months 
- Easy to perform 
- Tumour progression studies 
- Long waiting time to increase 
efficiency 
- Variable mutational spectra 
Xenograft 
(cells) 
- Unlimited starting material 
- Can model metastasis 
- Easy to perform (subcutaneous) 
- Human tumours modelling 
- Drug testing 
- Poor predictive value 
- Loss of heterogeneity of starting 
culture 
- Cells change when grown in vitro 
- Difficult to perform (kidney capsule) 
Xenograft  
 (patient-derived) 
- Recapitulate tumour of origin 
- Recreate tumour heterogeneity 
- Can model metastasis 
- Easy to perform (subcutaneous) 
- Human tumours modelling 
- Personalised treatment 
- Efficiency is low for some tumour 
types 
- Lack of standardization 
- No early tumorigenesis studies 
- Difficult to reproduce human immune 
system 
- Difficult to perform (kidney capsule) 
GEMs 
- Gene function studies 
- Early tumorigenesis studies 
- Temporal and spatial mutagenesis 
- Tumour progression studies 
- Gene-specific drug testing 
- Expensive 
- Time consuming to generate 
- Labour intensive 
Organoid 
cultures 
- Human model  
- Can recapitulate tumour histology 
- More heterogeneous than cell lines 
- Genetically stable 
- Bulk drug testing 
- Less expensive than animal models 
- New model that needs validation 
- Not available for all tissues 
- More expensive than cell lines 
- No microenvironment 
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1.5.1 Cell lines to model liver cancer 
Cancer cell lines have been extensively used to model cancer and have been 
established from many normal and cancerous tissues, most of which are available and 
can be found on repository websites such as the American Type Culture Collection 
(ATCC).  
The implementation of cell lines in cancer research has helped not only in increasing 
our knowledge of the cancer cell itself and its molecular biology, but has also been 
exploited to test drug sensitivity, resistance and toxicity (Sharma, Haber, and 
Settleman 2010; Lin and Will 2012). As an example of this, the anticancer drug 
Sorafenib, currently used as targeted therapy for HCC, has been initially shown to 
inhibit proliferation and induce apoptosis in two HCC cell lines (Hep2G and 
PLC/PRF/5) and then also in a tumour xenograft model, proving the usefulness of 
cancer cell lines for drug testing (Liu et al. 2006). However, it is not always possible to 
derive stable cell lines from all tumour types. More specifically, only two cancer cell 
lines from intrahepatic CC have been established so far, thus greatly limiting the use 
of cell lines to model this disease (Ku et al. 2002; Cavalloni et al. 2016). 
Although the use of cell lines has been instrumental over the years, their 2D structure 
fails to fully recapitulate the in vivo counterpart. As a result, the knowledge obtained 
from studies using cell lines is merely indicative and often will need validation in other 
cancer models. To overcome this issue, cell lines have been cultured using bioreactors 
or supporting matrices that allow cells aggregation in a 3-dimensional fashion. These 
structures, termed spheroids, are more likely to recapitulate tumour physiology in vivo 
and have been able to maintain some of the liver-specific activity and architecture 
(Mueller, Koetemann, and Noor 2011; Bokhari et al. 2007; Tostões et al. 2012). 
Nevertheless, they still do not recapitulate the histology and genetics of patient 
tumours. 
 
1.5.2 Animal models of liver cancer 
Animal models have been extensively used to gain insights into tumour biology and 
responses to drug treatments. To model liver cancer using animal models there are 
several approaches that have been developed so far, including chemically-induced 
mutagenesis, xenograft transplants and genetic modification.  
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Chemical induced hepato-carcinogenesis 
The carcinogen diethyl nitrosamine (DEN) is one of the most common chemicals used 
to induce HCC formation in the liver (Tolba et al. 2015). DEN causes DNA damage 
and random mutagenesis due to oxidative stress after being metabolised by the 
cytochrome P450 in the hepatocytes. Administration of DEN results in HCC formation 
after about a 6 months latency period, with tumour incidence increasing to 100% after 
longer periods of time (Tolba et al. 2015). Major limitations of this system are the long 
waiting time to get 100% of adenomas (> 6 months) and the lack of liver fibrosis, usually 
associated with human HCC. To overcome these issues, new protocols have been 
implemented using a combination of DEN and CCl4. As previously mentioned, CCl4 is 
a toxic agent that kills the hepatocytes around the CV but also induce an inflammatory 
response. Long-term administration of CCl4 have been shown to induce nodule 
formation in mouse livers, alone or in combination with other agents (Confer and 
Stenger 1966; Takeki Uehara, Pogribny, and Rusyn, n.d.). When combined with DEN, 
CCl4 is administered to mice 2 times a week for a total of 17 to 22 weeks after being 
primed by one injection of DEN. This system has allowed for faster tumour growth in a 
setting of liver fibrosis, better representing the human tumour counterpart (Takeki 
Uehara, Pogribny, and Rusyn, n.d.; T. Uehara et al. 2013). Of note, there are currently 
no models to chemically-induce CC growth. 
 
Xenograft models 
Xenograft models consist of inoculating a human cell suspension or a tissue fragment 
directly into mice either subcutaneously or orthotopic. Engraftment of cells or tissue 
will generate tumours in the host organism. When cells or tissues are taken directly 
from a human patient the model is called patient-derived xenograft (PDX). While 
engraftment of in vitro expanded cells has been used to model cancer (Reiberger et 
al. 2015), they fail to fully recapitulate the histology, genetics and heterogeneity of the 
original tumour. By contrast, PDX models have the ability of retaining these features 
also after passaging through mice (Hidalgo et al. 2014). Importantly, a large panel of 
PDX models of HCC have been recently used to assess the effectivity of Sorafenib, 
drug commonly used to treat HCC, and Lenvatinib, fibroblast growth factor receptor 1 
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(FGFR1) inhibitor, proving different responses based on genetic profile (Gu et al. 
2015). 
Being easy to perform, subcutaneous xenograft models are most commonly used to 
model HCC. In this model, drugs can be administered either systemically or locally by 
direct injection into the tumour mass. However, this system lacks the interaction 
between the forming tumour and the liver tissue. When such interaction is required, 
orthotropic xenograft models, where cells are injected directly into the hepatic lobes, 
can be considered instead. This model is also preferred for metastatic studies, as 
tumour cells are more likely to metastasise to other tissues. Alternatively, kidney 
capsule xenograft has also been used to model several cancer types, as it provides a 
good environment for tumour growth and to model metastasis. 
 
Genetically engineered mouse (GEM) models 
GEM models are a powerful alternative to the other methods described above. These 
models rely on the genetic modification of human cancer-related genes (oncogenes 
and/or tumour suppressor) to induce tumour formation in mice. The increased 
knowledge of the mutational spectra of liver cancer has also allowed for the use of this 
system to examine the contribution of newly-found mutated genes to cancer formation. 
Also, the knowledge of some of the mutations present in the tumour itself has made 
drug testing for targeted therapy in an in-vivo setting easier. 
Overexpression of oncogenes and/or deletion of tumour suppressor genes can be 
performed both constitutively or in a spatial and temporal inducible manner. To 
generate a GEM model, the desired modification is inserted in the DNA of an 
embryonic mouse cell which is subsequently injected into an embryo to produce a 
chimera. When germline transmission is achieved, the genetic modification will be 
passed to the progeny. In case of constitutive genetic models, all the cells will be 
affected at all developmental stages. One of the first models of this type used the 
constitutive expression of Hepatitis B virus x (HBx) protein to rule out the association 
of Hepatitis B infections with cancer formation (Kim et al. 1991). Of note, this study 
proved that expression of the HBx protein alone was able to induce adenoma formation 
at the age of 8-10 months in mouse models (Kim et al. 1991). 
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In some cases, constitutive DNA modification can affect the proper development of the 
organism and result in lethality, thus limiting the use of this technology. Many systems 
have been devised to overcome this issue. One of the most popular strategies is the 
Cre/LoxP system, that allows to induce the desired modification only in a specific cell 
population (Zhang et al. 2012). The system relies on the expression of a Causes 
Recombination (CRE) protein whose gene is located downstream of a tissue-specific 
promoter. Upon expression, the CRE protein directs the excision of a DNA region of 
interest previously flanked by loxP sites (floxed) (Figure 1.7) (Zhang et al. 2012). The 
system has been further improved to allow temporal control of the excision. In the 
updated system, the CRE protein is fused together with a tamoxifen-dependent version 
of the estrogen receptor (ERT2). Hence, only when the drug tamoxifen is injected into 
the mouse, the CRE-ERT2 fusion protein can translocate to the nucleus and drive the 
DNA excision. This allows to perform DNA modification after birth and removes the 
lethality problem (Figure 1.7) (Zhang et al. 2012). Over the years, the CRE-ERT2 
system has been extensively used to study gene functions and to model cancer. In the 
liver, one of the most common promoter used to drive liver-specific modification is the 
albumin promoter. In this case, the genomic modification is exerted only albumin-
expressing cells, the hepatocytes, and only in presence of tamoxifen if using the 
inducible system (Schuler et al. 2004). 
Cre/LoxP system has been used to assess genes contribution to cancer either alone 
or in combination. For instance, hepatocyte-specific knock-out of Pten (Phosphatase 
and Tensin Homolog) has shown to induce adenoma formation and also HCC at lower 
percentage, proving its tumour suppressor activity in the liver (Horie et al. 2004). 
Similarly, deletion of both Rb (Retinoblastoma) and Tp53, using a Cre protein whose 
expression was driven by the Alb (Albumin) promoter, induces HCC formation after 
DDC diet-induced damage (Nantasanti et al. 2016). Albumin is expressed in 
hepatoblasts that give rise to both hepatocytes and cholangiocytes in the adult liver, 
thus Cre mediated modifications will be present in both cell types. In line with this, the 
use of the AlbCre system has also allowed the generation of models for CC. A few 
examples includes the overexpression of the intracellular domain of the Notch receptor 
(NICD) or a mutated form of Idh1, both driven by Albumin-Cre, and resulting in CC 
development during adulthood (Saha et al. 2014; Zender et al. 2013).  
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1.5.3 Organoid cultures, the new frontier of modelling 
Recently, a novel 3D ever-expanding culture system, termed “organoid”, has been 
established from various mouse and human tissues including small intestine, colon, 
stomach, pancreas and liver, opening up new possibilities for disease modelling (Sato 
et al. 2009; Huch, Dorrell, et al. 2013; Huch, Bonfanti, et al. 2013; Stange et al. 2013; 
Huch et al. 2014; Boj et al. 2014; Bartfeld et al. 2014) (Figure 1.8a). In this system, 
adult stem cells are harvested from the tissue and then embedded in matrigel, a 
basement membrane matrix, where they can expand and organize into epithelial 
structures of the respective organ of origin. Of note, the cells are not transformed, as 
with established cell lines, but are obtained directly from the original primary tissue. 
Moreover, the cells preserve their cellular identity in vitro, giving rise only to cell types 
of the tissue of origin (Simmini et al. 2014). Importantly, organoid cultures have been 
proven to be highly genetically stable, as no abnormalities in chromosomes number 
have been detected during the culturing periods and single base changes occurred at 
very low rate (Blokzijl et al. 2016). 
	
Figure 1.7. Schematic representation of functioning of CRE-loxP system. CRE proteins are always 
active and translocate to the nucleus once expressed. CRE-ERT2 proteins are trapped in the cytosol 
by Hsp90. However, the binding with tamoxifen is able to free CRE-ERT2 from HSP90 and allow its 
nuclear localization. Once in the nucleus, CRE or CRE-ERT2 drives recombination and excision of a 
DNA region flanked by loxP sites. 
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The first kind of organoid culture established is from the gut epithelium, where intestinal 
crypt Lgr5+ stem cells were isolated and seeded in culture. After addition of specific 
growth factors to activate proliferative pathways (R-spo1, EGF and Noggin), the cells 
would proliferate, differentiate and organise in 3D structures resembling the in-vivo 
intestinal villus-crypt pattern, still preserving their renewal potential (Sato et al. 2009). 
After that, similar studies have been performed in order to reproduce these results with 
other tissue types. In 2013, two studies from the Clevers group were published, 
presenting their data on organoid cultures from the mouse liver and pancreas (Huch, 
Dorrell, et al. 2013; Huch, Bonfanti, et al. 2013). Specifically, Huch et al. found that, 
after damage, Lgr5 also mark a stem cell population in the liver and that these cells 
can be grown and expanded in-vitro indefinitely (Huch, Dorrell, et al. 2013). In order 
for the adult liver cells to grow and form organoids, they need several stimuli, including 
FGF (fibroblast growth factor), HGF (hepatocyte growth factor) and EGF (epithelial 
growth factor) signalling, but also activation of the WNT pathway by addition of the 
WNT agonist R-spo1. Crucially, the mouse liver organoid culture protocol has been 
recently adapted to allow long-term expansion of single human liver stem cells (Huch 
et al. 2014). In addition to the growth factors needed for the culturing of the mouse liver 
organoids, the human ones also need inhibition of TGFb (transforming growth factor 
beta) signalling and addition of FSK (forskolin), a cyclic AMP (adenosine 
monophosphate) activator, in order to achieve long term expansion. In contrast with 
the intestinal organoids where different cell types compose the villus-crypt structures 
in-vitro, liver organoids are made predominantly of ductal/progenitor cells assembled 
in a single layer epithelium to form cystic structures (ductal phenotype). However, both 
mouse and human liver organoids have been induced to differentiate into hepatocyte-
like cells in-vitro that retains some of the function of the cells in-vivo (e.g. albumin 
secretion, cytochrome activity) (Figure 1.8b). In addition, liver organoids are able to 
differentiate into hepatocyte also after transplantation in-vivo. To prove the usefulness 
of this system, Huch et al. have also established organoids from human livers affected 
by α1-antitrypsin (A1AT) deficiency and Alagille syndrome and used them to model the 
disease in-vitro (Huch et al. 2014).  
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Strikingly, the ability of establishing organoid cultures starting from adult stem cells has 
also made possible the growth of tumour-derived organoid cultures, termed tumoroids. 
Specifically, tumoroids have been grown from mouse and human colon, pancreas and 
prostate cancers, but never from liver cancer (Li et al. 2014; Sato et al. 2011; van de 
Wetering et al. 2015; Boj et al. 2014; Gao et al. 2014). Tumoroids have been shown to 
closely resemble the tumour of origin, by being able to recapitulate some of the 
	
Figure 1.8. Adult stem cell-derived organoid cultures. a) Schematic representation of the different 
organoids that can be derived from adult human stem cells. Lg, Lung; Lv, Liver; Ma, mammary gland; 
Pc, Pancreas; Pr, Prostate; St, Stomach; Tg, Tongue. b) Mouse and human liver organoids are 
generated culturing a duct or a duct cell in medium supplemented with E (EGF), F (FGF10), H (HGF), 
Nic (nicotinamide) and Rspo. Ti (TGFbi) and A (forskolin) (in blue) are required for the growth of human 
liver organoids. When in expansion medium, cells expand as ductal structures (PCK, pan-cytokeratin, 
red). When cultured in differentiation medium, cells differentiate into a polygonal-like epithelium 
expressing hepatocyte markers (albumin, red; ZO1, green). Adapted from Huch and Koo 2015.	
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histological features observed in the original tissue, but also by presenting a matching 
mutational pattern. The ability of tumoroids of modelling cancer has also been proven 
upon xenotransplantation in vivo, where only tumour-derived organoids, and not 
healthy tissue-derived ones, are able to engraft, grow, form tumours and, in some 
cases, give metastasis, thus representing a good new model for cancer in vitro and a 
valuable alternative to cancer cell lines. As tumoroids also recapitulate genetic features 
of the original tumour, they have also been used for screening of drugs for personalised 
treatments. Specifically, van de Wetering et al. have established a biobank of 20 
tumoroids from human colorectal cancer patient (van de Wetering et al. 2015). After 
characterisation of the lines to assess their modelling potential, they subjected some 
of them to drug testing. Interestingly, they observed a good correlation between drug 
effect and genetic profile of the culture, making this system useful also to devise both 
new targeted and personalised therapies. However, as tumours are highly 
heterogeneous and tumoroids originate from a small biopsy of the original tumour, they 
might not represent the whole heterogeneous population of the tissue of origin. Thus, 
these data need to be confirmed after validation of the heterogeneity of the tumoroid 
lines used in order to translate this into a therapeutic approach. 
Finally, genome engineering of organoids using the CRISPR-Cas9 technology has 
further proved the usefulness of this system to model diseases (Matano et al. 2015; 
Drost et al. 2015) (discussed in next paragraph). These data suggest that organoids 
not only are a good system to study stem cell physiology but they can also represent 
a valid tool for disease modelling. 
 
1.5.4 The CRISPR-Cas9 technology 
Genome engineering of cells have been made easier and faster by the implementation 
of the CRISPR-Cas9 technology. Originally discovered to be part of the adaptive 
immune system that prokaryotic cells adopt to fight viral infections, it has recently been 
adapted to perform knock-outs and precise gene editing in cells derived from different 
organisms (Ran, Hsu, Wright, et al. 2013). The acronym CRISPR stands for ‘clustered, 
regularly interspaced, short, palindromic repeats’, while Cas9 is the CRISPR-
associated endonuclease. A single guide RNA (gRNA) is used by Cas9 to recognised 
a 20bp target sequence downstream of a conserved protospacer adjacent motif (PAM) 
(Figure 1.9a). In the absence of a DNA template for homologous recombination, the 
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Cas9 endonuclease generates double-strand breaks that are then ligated back 
together by the DNA repair machinery via NHEJ (non-homologous end joining). Since 
this process is inherently error-prone, the insertion or deletion of a nucleotide(s) 
frequently occurs, resulting in frameshift mutations and inactivation of the target gene 
(Ran, Hsu, Wright, et al. 2013) (Figure 1.9b). Alternatively, when a donor vector is co-
delivered together with gRNAs and Cas9, it is possible for repair to occur via 
homologous recombination, which therefore allows precise gene editing through 
knock-in (Figure 1.9b). 
Interestingly, recent reports have shown that CRISPR-Cas9 can be used to perform 
genome engineering of organoid cultures. As originally shown by Schwank et al., 
human intestinal organoids can be easily genetically manipulated using CRISPR, 
allowing human disease modelling (Schwank et al. 2013). Two further independent 
studies have used human intestinal organoid cultures to model colorectal cancer after 
introducing mutations in cancer-related genes in healthy cultures using the CRISPR 
technology (Matano et al. 2015; Drost et al. 2015). Using restricted media condition, 
mutated organoids can easily be selected. For instance, organoids mutated in Apc, 
were selected by removing Rspo1 from media condition, thus allowing only mutated 
cells to survive. Similarly, only organoids mutated in Kras survived after withdrawal of 
EGF. Interestingly, CRISPR-generated tumoroids acquired feature of malignant 
transformation and were able to form tumours after subcutaneous injection or 
implantation in the kidney capsule of mice, suggesting that this could be a new valid 
method to generate cancer models. 
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Figure 1.9. The CRISPR/Cas9 technology. a) A single gRNA (red sequence is the gRNA scaffold; 
blue sequence is 20bp complement to target region) is used by the endonuclease Cas9 (in yellow) to 
recognize a 20bp region on the DNA target and perform a cut 3bp upstream of a PAM sequence. PAM 
sequence 5’-NGG is essential in order for the Cas9 to cut the target sequence. A double strand break 
(DSB) is performed 3bp upstream of the PAM (red triangle) (Ran, Hsu, Wright, et al. 2013). b) DSB is 
repaired either by non-homologous end joining (NHEJ) introducing indel mutations in the sequence or, 
if a donor template is provided, by homology directed repair (HDR), allowing precise gene editing(Ran, 
Hsu, Wright, et al. 2013). c) More recently, a mutated version of the Cas9, termed Cas9 nickase 
(Cas9n), able to cut only one strand of the DNA, has been implemented to increase the specificity of 
the cut (Ran, Hsu, Lin, et al. 2013). Here, DSB is achieved by the use of two adjacent gRNAs that 
recognize 20bp sequences on opposite strands of the DNA. Off target effect is thus reduced to a 
minimum as two cutting sites close two each other are required to obtain a DSB. Adapted from Ran et 
al., 2013 (Ran, Hsu, Wright, et al. 2013). 
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2. AIMS 
 
Primary liver cancer (PLC) is the second most common cause of cancer death 
worldwide. Treatment for PLC usually involves surgical resection of the tumour, 
transplantation and chemotherapy and/or radiotherapy. Current models for PLC either 
fail to fully recapitulate tumour histology and architecture or are expensive, time-
consuming and do not allow for personalised drug testing. The unavailability of specific 
drugs and the lack of possibility for personalised treatment makes this disease difficult 
to treat. With this work, I aim at generating new and different approaches to model liver 
cancer both in vivo and in vitro, and to use those approaches to investigate the role of 
genes newly found mutated in this disease.  
- To establish a new reliable method for liver cancer modelling, together with Dr. 
Laura Broutier, I have sought to investigate the possibility of generating liver tumour-
derived organoid cultures (tumoroids) from human liver cancer biopsies.  Human 
organoid cultures have been established from many normal and cancerous tissues, 
proving their usefulness in disease modelling in vitro.  This system, could allow 
modelling PLC in a human system in vitro, but could also be pivotal for establishing 
personalised treatment for patients. 
- To gain insight about the role of specific genes to cancer initiation and 
progression, I will generate a protocol for introducing mutations in cancer-related 
genes in human liver organoid cultures using the CRIPR/Cas9 technology. The use of 
this in vitro tumour model system with a known mutational spectrum could help unravel 
a specific mutation’s contribution to cancer formation. In addition to this, this 
technology could be used as a screening platform before commencing animal work. 
- The last objective of my PhD has been to investigate the role of RNF43 and 
ZNRF3 (R&Z) in the liver during homeostasis and regeneration, and also to study their 
role in cancer formation. R&Z are two homologous negative regulators of the WNT 
pathway and have been found mutated in many cancer types, including liver. Very little 
is known about the role of these two genes in the liver and this study will help broaden 
our understanding on the implication of their inactivation in this tissue. 
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3. RESULTS - PART I 
 
Establishment and characterisation of 
patient-derived organoid cultures to 
model primary liver cancer in vitro 
 
3.1 Summary 
Primary liver cancer (PLC) is one of the deadliest cancer worldwide. There are already 
several models for PLCs, which include the use of cell lines and animal models. Cell 
lines have been extensively used for drug testing, although they fail to recapitulate 
tumour histology and/or genetics. Conversely, animal models, and more specifically 
PDX models, can very well recapitulate the features of the tumour of origin but they 
are expensive and not suitable for massive drug screening. New model systems that 
recapitulate tumour architecture and, at the same time, allow efficient drug testing are 
currently not available. In this section, I present PLC-derived organoid cultures 
(tumoroids) as a new model strategy for PLC.  
In collaboration with Dr. Laura Broutier, we have found that tumoroids can be 
established from PLC, including HCC, CC and the combined subtype CHC. 
Importantly, tumoroids can expand long-term and recapitulate both histological and 
genetic features of the tumour of origin. For instance, they have high percentage of 
aneuploidy and present mutations found in the patient’s original tumours. Strikingly, 
the mutational profile of tumoroids can be used to predict drug sensitivity and 
resistance in-vitro. Finally, tumoroids are also able to induce tumour formation that 
resembles the tumour of origin in mice. 
These data show the great potential of this new model system that, not only 
recapitulates patient’s tumours of origin, but can also be used for drug screening as a 
personalised medicine approach. 
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3.2 Establishment of patient-derived cancer organoid cultures 
I have worked in collaboration with Dr. Laura Broutier to establish a novel system to 
culture liver tumour cells in vitro, by adapting the previously described protocol for 
culturing human liver cells (Huch et al. 2014). Both normal and cancerous tissues 
biopsies were obtained from PLC patients with no history of viral-mediated hepatitis. 
Tissues were dissected and divided into four parts. One part was used for organoids 
derivation and the remaining ones for histology, genome and expression analysis as 
shown in Figure 3.1. For organoids derivation, tissue was dissociated to single cells, 
seeded in BME/2 matrix and monitored for forming organoid structures.  
 
By following the previously established protocol with modified culturing conditions, we 
have established PLC-derived organoid (tumoroids) cultures from 8 different PLC 
patients, including moderate/well differentiated HCC (n=3), CC (n=3), and combined 
HCC/CC (CHC; n=2) (Figure 3.3). Of note, we were unable to establish cultures from 
well differentiated HCCs, probably due to the very low percentage of proliferative cells 
in these samples. 
Tumoroids were expanded long-term in culture and were passaged weekly at a ratio 
of 1:4/1:5, CC organoids, or every 10 days at a ratio of 1:3, HCC and CHC organoids, 
reflecting the proliferative state of the tissue they derive from (Figure 3.2). It was not 
possible to expand HHC-2 for longer than 1 month due to the elevated presence of 
fibroblasts, which outcompeted the tumoroids growth (Figure 3.2). 
	
Figure 3.1. Experimental design for establishment of patient-derived tumoroid cultures. Tumour 
samples were collected from human HCC, CHC and CC tumours. For each tissue, samples were split 
into 4 parts and processed for histology, RNA and DNA isolation, and for tumoroid derivation. To 
establish the tumoroid cultures, biopsies were dissociated to single cells and seeded in BME/2 using 
appropriate medium conditions. 
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At microscopic observation, tumoroids present heterogeneous morphological features 
(Figure 3.3). Overall, they lost the cyst-like hollow structure of healthy organoids and 
presented themselves as either compact structures (HCC and CHC) or as irregularly-
shaped cyst-like structures (CC). To further corroborate this observation, we performed 
H&E staining of formalin-fixed paraffin-embedded tumoroids sections. As previously 
reported, healthy organoids are formed by a single layer of cells and mimic the ductal 
compartment of the liver (Huch et al. 2014). On the other hand, tumoroids exhibit 
aberrant structures and features that can also be found on the tissue of origin (Figure 
3.3). For instance, CC tumoroids have extensive glandular domains with carcinoma 
cells invading the lumen. Meanwhile, HCC and CHC tumoroids exhibit a solid and filled 
structures and, in case of HCCs, also presenting pseudo-glandular domain typical of 
HCC tissues.  
Overall, tumoroids can be established from several liver cancer types, can be 
expanded long-term and recapitulate histological characteristic of the tissue of origin 
and cancer subtype. 
	
Figure 3.2. Tumoroids can be expanded long-term. After generation of the tumoroid lines, the 
cultures were expanded and passaged according to their growing potential. Graph indicating the 
expansion potential of tumoroids cultures established and their correlation to the expansion of healthy-
tissue derived organoids.  Arrow, continuous expansion. Dot, passage.	
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Figure 3.3. Tumoroids recapitulate the histologic features of the patient’s tissue of origin. 
Representative H&E staining of healthy liver tissue and primary tumour (left column), and corresponding 
bright field microscopy images (middle column) and H&E histological analysis of the organoid lines 
derived from these (left column). *, duct; L, lumen; arrowheads, pseudoglandular domains. Scale bars, 
100µm. 	
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3.3 Tumoroids present genetic alterations and can be used for 
drug testing 
Liver tumours present high percentage of aneuploidy and are characterized by defined 
genetic alterations. For this reason, we sought to analyse whether tumoroids would 
also recapitulate genetic abnormalities. As previously described, healthy tissue-
derived organoids exhibit normal chromosome number with very low somatic base 
substitutions in coding regions that arise either in vivo or during culture derivation 
(Huch et al. 2014). Consistently with this, we found no chromosomal alterations in 
healthy-derived organoids (Figure 3.4a, b). Conversely, all the tumoroids lines we have 
generated presented multiple chromosomal aberrations with both gain and/or loss of 
chromosome numbers (Figure 3.4a, b). 
 
	
Figure 3.4. Tumoroids are aneuploid and recapitulate the genetic alterations of the patient’s 
tissue of origin. a, b) Healthy organoids and tumoroids were treated with Colcemid reagent to halt 
proliferation during metaphase and were then processed for chromosome analysis and count. Graph 
represents ploidy analysis of organoid cultures derived from healthy/donor organoids (n=1), HCC (n=2), 
CHC (n=2) and CC (n=3) tissues and indicates the % of chromosomes counts present in each sample. 
Results are expressed as % of ploidy per number of metaphases counted (Healthy_O, n=26; HCC-1_O, 
n=38; HCC-2_O, n=20; CHC-1_O, n=25; CHC-2_O, n=25; CC-1_O, n=58; CC-2_O, n=44; CC-3_O, 
n=23). Experiment was performed at least in duplicate. Pictures are representative of organoid 
metaphases used for the ploidy analysis. (c) Whole exome sequencing was performed on DNA 
extracted from both primary tissue and respective tumoroid cultures. Tables show genes altered in 
organoid cultures and known to be mutated in liver or gastrointestinal tumours.	
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To further analyse the genetic alterations of our model system, we have then 
performed whole exome sequence analysis on one of each subtype of liver tumoroids, 
namely HCC-1_O, CHC-1_O, CC-1_O and corresponding patient’s tissue. 
Interestingly, tumoroids exhibited different mutational patterns that reflected their 
subtype of origin (Figure 3.4c). Specifically, HCC tumours have high incidence of 
mutations in genes belonging to the Wnt signalling pathway and consistently, CTNNB1 
was found mutated in HCC-1_O tumoroids. Instead, homozygous mutations of RNF43, 
the only Wnt pathway-related gene found mutated so far in CCs, and heterozygous 
mutations of ARID1A and ARID1B, were found in CC-1_O tumoroids. In addition, 
KRAS (KRASG12D) mutations were also found in CC-1_O and in CHC-1_O, but not 
in HCC-1_O, consistent with the subtype mutational profile. Importantly, all mutations 
found in the tumoroids were also found on the patient’s tumour of origin, further 
validating the model system. 
Knowing the mutational spectra of HCC-1_O, CHC-1_O and CC-1_O tumoroids, we 
sought to investigate whether we could use this knowledge to predict tumour drug 
sensitivity and resistance in vitro. To this purpose, we have cultured HCC-1_O, CHC-
1_O and CC-1_O with the porcupine inhibitor IWP2 and the epithelial growth factor 
receptor (EGFR) inhibitor Gefitinib (Figure 3.5a, c).  
The porcupine inhibitor IWP2 prevents WNTs secretion, thus it inhibits the WNT 
pathway and bears death to cells in which the pathway is not constitutively active. In 
line with this, organoids derived from healthy donors are not able to survive when 
cultured in presence of IWP2 (Huch et al. 2014). Consistent with the identified mutation 
in CTNNB1, HCC-1 tumoroids were able to survive and expand in presence of IWP2 
(Figure 3.5a). On the other hand, Healthy-1_O, CHC-1_O and CC-1_O organoids did 
not survive the treatment. This data was suggesting that the RNF43 mutations 
identified in CC-1_O were not enough to confer Wnt independency, consistent with the 
results observed in the mouse intestine (Koo et al. 2015). In addition, the IWP2 
treatment did not affect the expression of the Wnt target genes AXIN2, LGR5 and 
TNSFRS19 only in HCC-1_O tumoroids, suggesting that the CTNNB1 mutation 
detected in this sample was enough to drive constitutive WNT pathway activation and 
WNT independency (Figure 3.5b). 
Similarly, when HCC-1_O and CC-1_ tumoroids were treated with the EGFR inhibitor 
Gefitinib, CC-1_O were able to grow and expand, according to their mutations in 
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KRAS, but not healthy organoids and HCC-1_O tumoroids, where no mutations in the 
EGF signalling pathway were detected (Figure 3.5c). 
 
Overall, tumoroids show extensive chromosomal abnormalities and recapitulate the 
genetic spectrum of the tumour subtype of origin. Importantly, tumoroids can be used 
to predict and test drug sensitivity and resistance according to their mutational profile. 
 
 
	
Figure 3.5. Tumoroids can be used for drug testing and to predict drug sensitivity a) 
Representative bright field microscopy images of organoid cultures derived from healthy-1, HCC-1, 
CHC-1 or CC-1 tissues tested for their sensitivity to treatment with the porcupine inhibitor IWP2 (3 μM) 
(1 of 3 independent experiments). Cultures were dissociated to single cells and then seeded in medium 
containing the drug. Pictures were taken 3 weeks after the seeding. Scale bars, 500µm and 100 µm 
(insets). b) RT-qPCR expression analysis of the Wnt target genes LGR5, AXIN2 and TNFRSF19 on 
IWP2 treated cultures. Fold change was calculated relative to the expression on the vehicle-treated 
control (DMSO control). Results are expressed as mean ± STD of 2 independent experiments. c) 
Representative bright field microscopy images of organoid cultures derived from Healthy-1, HCC-1 and 
CC-1 tissues tested for their sensitivity to treatment with the EGFR inhibitor Gefitinib (1 μM) (1 out of 2 
independent experiments). Cultures were dissociated to single cells and then seeded in medium 
containing the drug. Pictures were taken 3 weeks after the seeding. Scale bars, 500µm and 100 µm 
(insets). 
	 -	37	-	
 
3.4 Tumoroids model tumour subtype and metastasis in vivo 
To determine whether tumoroids have the potential to give rise to tumours in vivo and 
to recapitulate patient’s tumour histology even after long term expansion in culture (>3 
months), we performed subcutaneous grafting of HCC-1_O and CC-1_O tumoroids 
and kidney capsule transplant of CC-1_O tumoroids in immunocompromised NSG 
mice (Figure 3.6). 
To perform subcutaneous xenograft experiments, a total of ~1 million cells were 
injected under the skin of immunocompromised mice. Healthy organoids were used as 
control. Mice were monitored constantly for tumour growth and analysis was performed 
at 1 and 5 months after the injections. Tumour outgrow was found in animals injected 
with CC-1_O (6/6) and HCC-1_O (4/6) but not in animals injected with healthy 
organoids (0/12) (Figure 3.7). Interestingly, CC-1_O derived tumours presented a 
strong stromal reaction with glands formation and cribriform structures, reminiscent of 
the CC-1 patient’s original tissue (Figure 3.7a). Similarly, pseudo-glandular structure 
resembling those found in HCC-1 patient’s original tissue could also be observed in 
HCC-1 tumoroid-derived tumours (Figure 3.7b). 
To test the metastatic potential of the tumoroid cultures, we injected CC-1_O cells, 
derived from a patient with history of metastasis, into the kidney capsule of 
immunocompromised NSG mice (Figure 3.8). Mice were analysed 0.5, 1, 2 and 3 
months after injection. In all cases (9/9) mice developed tumours in the kidney, as 
	
Figure 3.6. Experimental design of xenograft transplant. PLC tumoroids or healthy organoids were 
transplanted subcutaneously (SC) or under the kidney capsule (Kid.Cap.) of immunocompromised NSG 
mice and analysed for the presence of tumour growth and metastasis at different time points.	
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confirmed by KRT19 staining (Figure 3.8a, c). Like in the subcutaneous grafting, 
tumours resembled the original patient’s tissue. More importantly, 7 out of 9 mice also 
developed secondary metastatic nodules in the lungs proving that CC-1_O can retain 
the metastatic potential of the cells in vivo even after long term expansion in culture 
(Figure 3.8b). 
 
	
Figure 3.7. Tumoroids induce tumour formation in vivo maintaining their identity. Tumoroids and 
healthy organoids were broken into pieces and then injected subcutaneously into nude mice. a) 
Representative H&E staining of CC-1 tumoroids transplanted subcutaneously (top) into NSG mice and 
corresponding CC-1 patient’s tumour sample (bottom). Arrowheads, desmoplasia.  Scale bars are top 
left 250µm; top right 125µm; bottom left 125µm and bottom right 62.5µm. b)  Representative H&E 
staining of HCC-1 tumoroids transplanted subcutaneously (top) into NSG mice and corresponding HCC-
1 patient’s tumour sample (bottom).  Dashed circles, pseudoglandular domains. Scale bars are left 
125µm and right 62.5µm. c) Table summarizing the number of cells injected and the number of tumours 
formed. 	
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Overall, these data show that tumoroids can give rise to tumours in vivo that faithfully 
recapitulate the tumour subtype histology and retain patient’s tissue of origin features, 
including the metastatic potential even after long-term expansion in culture. 
 
 
 
 
	
Figure 3.8. Tumoroids recapitulate metastatic potential of the tumour of origin. a) Representative 
H&E (left) and KRT19 (right) immunochemistry analyses of CC-1 tumoroids transplanted under the 
kidney capsule into NSG mice. Scale bars, 125µm. b) Lung metastases derived from the human CC-1 
tumoroids transplanted under the kidney capsule cells (right panels) were identified using a human 
specific KRT19 antibody. Scale bars, 500µm, magnification 125µm. c) Table summarizing the number 
of cells injected and analysis of tumour and lung metastasis.	
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4. RESULTS - PART II 
 
CRISPR/Cas9 genome engineering of 
human liver organoid to model liver 
cancer in vitro 
 
4.1 Summary 
Tumoroids can have different applications and may contribute to better understanding 
tumour biology. More importantly, tumoroids may facilitate discovery of new drugs to 
use as targeted therapeutic strategy. However, their use resents limitation when aiming 
at studying specific genes and their contribution to cancer formation. To overcome this 
issue, in this section I will present a different approach, involving the use of 
CRISPR/Cas9 genome engineering to specifically introduce PLC-related mutations in 
healthy human liver organoid cultures. 
Applying the CRISPR/Cas9 technology to human liver organoids I have successfully 
introduced indel mutations in TP53, RNF43 and ZNRF3. Interestingly, when mutating 
TP53, organoids acquire histology and genetic aberrant features reminiscent of 
malignant transformation. To test the ability of this system to study less known 
mutations, I have generated R&Z double mutants organoids, showing for the first time 
a role for R&Z in the WNT pathway in a human setting and specifically in the liver, 
similar to what has been previously described in the mouse intestine (Koo et al. 2012). 
Interestingly, when TP53 and R&Z were mutated together, organoids resembled, in 
part, the patient’s derived tumoroids described in section 3.2. 
This data show that while mutations in TP53 could be driver of cancer in human liver 
cells, R&Z might instead have a role in tumour progression. Also, this system could 
represent a new method to test contribution of genetic mutations to cancer formation 
in human cells before using animal models, thus it may eventually facilitate gene 
function studies in human cancer research. 
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4.2 TP53 mutations induce phenotypic changes to healthy 
human organoids resembling malignant transformation 
To study gene functions and identify the contribution of genes to cancer formation, I 
have established a protocol for introducing indel mutations in healthy human liver 
organoids using the CRISPR/Cas9 system (Figure 4.1). Briefly, organoid cultures were 
dissociated to small clumps of 1-3 cells and subsequently transfected with a plasmid 
containing gRNA, Cas9 and a GFP. GFP+ transfected cells were sorted and seeded in 
BME/2 at low concentration to allow for clonal expansion. Clonal organoids were then 
isolated and screened for mutations. Whenever possible, positive clones were selected 
either by growth factor withdrawal or drug treatment. 
 
TP53 is frequently mutated in both HCC and CC and it is thought to be one of the early 
step in tumorigenesis (Guichard et al. 2012; Zou et al. 2014). For this reason, targeting 
TP53 was an obvious choice when trying to recapitulate a tumour phenotype using 
organoid cultures. To inactivate TP53, I have designed gRNAs targeting the DNA 
binding domain (DBD), essential to exert its function. After the generation of a plasmid 
containing gRNA targeting TP53, Cas9 and GFP reporter protein, human liver organoid 
cells were transfected using either lipofectamine 3000 or electroporation. Upon 
transfection, GFP+ cells were readily detectable after 24h incubation and were sorted 
after 48h incubation (Figure 4.2a). Clonally expanding cells were then isolated and 
maintained as separate cultures. To select for mutant clones with functionally inactive 
TP53, I have added Nutlin3 to the culture medium. Nutlin3 is a small molecule inhibitor 
that induces activation of TP53 and thus results in cell cycle arrest and/or apoptosis 
(Schug 2009; Hardcastle 2007). In this condition, only TP53 mutated cells were 
 
Figure 4.1. Schematic overview of CRISPR/Cas9 genome engineering workflow. Human liver 
organoids were derived from liver biopsies and then expanded and transfected with gRNA, Cas9 and 
GFP reporter gene. After 2 days of incubation, cells were sorted for GFP and seeded sparsely for clonal 
expansion and further analysis. 
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allowed to grow and expand (Figure 4.2b, c). Confirmation of mutation was done by 
Sanger sequencing analysis (Figure 4.2d). Using this approach, I have generated two 
independent lines with mutation in TP53. Interestingly, also the clone carrying in-frame 
mutations in TP53 was resistant to Nutlin3 treatment, suggesting functional inactivation 
of the DBD. Specifically, organoid formation efficiency of the two clones generated was 
not affected by the presence on Nutlin3 in the culture (Figure 4.2c). On the other hand, 
control culture from which the clones have been originated, but that has not been 
through the full procedure of transfection and sorting, was deeply affected by the 
treatment (Figure 4.2c). Of note, TP53 mutant organoids were smaller in size and had 
a slower growth rate when compared to control healthy organoids (Figure 4.2b). Mutant 
cultures eventually stopped expanding after a few passages, thus preventing full 
analysis of the culture. This difference might either be a direct effect of the TP53 
mutation, or a consequence of the stressful procedures the cells have been through. 
Further data need to be collected in order to rule out this hypothesis. 
 
	
Figure 4.2. TP53 mutated organoids resist Nutlin3 treatment. a) Pictures of transfected organoids. 
Arrows, GFP+ cells in an organoid. Scale bar, 250µm (left pictures) and 100µm (right pictures). b) 
Brightfield pictures of healthy and TP53 mutant organoids with and without Nutlin3 5µm. Scale bar, 
1mm. c) Graph showing organoid formation efficiency in normal condition and Nutlin3 (5µm) treated 
cultures. Data represent mean of technical replicates ± SEM. d) DNA sequence of mutated clones. 
RED, PAM sequence; BLUE, gRNA target sequence; ORANGE, insertion; -, deletion. Ref, reference; 
h, human; T, TP53; ins, insertion; del, deletion. 
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To further confirm TP53 inactivation, I have analyzed RNA levels of CDKN1A, 
downstream target of TP53. Strikingly, CDKN1A expression levels were highly reduced 
in both hT-/if-1 and hT-/--2 when compared to healthy not-processed TP53 wild-type 
donor organoids, further confirming successful inactivation of the gene. (Figure 4.3a).  
As TP53 is involved in maintaining the correct number of chromosomes during cell 
division, I have performed karyotype analysis to investigate the presence of 
chromosomal abnormalities, a hallmark of cancer. Surprisingly, both clones presented 
aneuploidy with multiple chromosomal gains (Figure 4.3b). This data suggests that the 
inactivation of TP53 alone is able to induce chromosomal abnormalities in human liver 
organoid cells. Of note, Healthy_O retained their chromosome number as expected 
and published in Huch et al. 2014. 
 
At microscopic evaluation, although TP53-mutated organoids were still preserving a 
cyst-like hollow structure typical of healthy organoids, they exhibited a thickening of 
the outer cell layers (Figure 4.4, brightfield).  
To investigate whether these changes were also reflected at histological level, I have 
performed H&E staining of formalin-fixed paraffin-embedded TP53-mutated organoid. 
Interestingly, CRISPR-mutated organoids presented tumour-like features. Specifically, 
both clones exhibited abnormal architecture, general thickening and multiple 
invaginations in the organoids lumen resembling tumour growth (Figure 4.4). These 
 
Figure 4.3. TP53 mutated organoids have low expression of CDKN1A and are aneuploid. a) 
Expression analysis for CDKN1A in mutant clones hT-/if-1 and hT-/--2 and healthy organoids. Data 
represent mean ± SEM. b) Healthy organoids TP53 clones were treated with Colcemid reagent to halt 
proliferation during metaphase and were then processed for chromosome analysis and count. Graph 
represents ploidy analysis of mutant organoid cultures and indicates the % of chromosomes counts 
present in each sample. Results are expressed as % of ploidy per number of metaphases counted 
(Healthy_O, n=15; hT-/if-1, n=15; hT-/--2, n=7).	
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data suggest that inactivation of TP53 in human liver organoid cells can drive 
phenotypical and structural changes resembling tumour formation. 
 
 
The phenotypic changes observed in the TP53-mutated organoids suggest that these 
cultures are losing their ductal nature in favour of a hepatocytes/tumour phenotype. To 
corroborate this hypothesis, I have analyzed the expression of common ductal and 
hepatocyte markers in the two mutant lines.  Remarkably, I have observed a decrease 
of expression of the ductal marker SOX9, but not KRT19, and an increase expression 
of the hepatocyte marker CYP3A4, but not HNF4α (Figure 4.5). These data might 
suggest that TP53-mutated organoids are changing their differentiation status. 
However, a more extensive analysis is needed to confirm this hypothesis. 
Overall, mutating TP53 in human liver organoid confer the cultures resistance to 
Nutlin3 treatment and more importantly, organoids acquire features of malignant 
transformation, including genetics and histologic alterations. However, as previously 
mentioned, mutant cultures stopped expanding after a few passages in cultures, 
making it difficult to confirm the results observed. 
 
Figure 4.4. TP53 mutated organoids acquire histologic tumoral features. Representative brightfield 
microscopy images (left column) and H&E histological analysis (middle column) of the CRISPR-mutated 
organoid lines. Scale bar, 100µm. Note difference between Healthy_O (single layer epithelium) and 
TP53 mutated cultures (thick organoid with budding structures).	
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4.3 R&Z mutations induce activation of WNT pathway in 
organoid cultures 
Having proved that the CRISPR-Cas9 technology can be applied to human liver 
organoid cultures, I asked whether this approach could be used to perform preliminary 
gene function studies of less known genes. To this purpose, I thought to investigate 
the role of RNF43 and ZNRF3 (R&Z) in liver using human liver organoids, as these 
genes have recently been associated with cancer and little is known about their role in 
liver. Of note, R&Z are homologous E3 ubiquitin ligases recently found to be negative 
regulators of the Wnt pathway and to have tumour suppressor role in the mouse 
intestine (Koo et al. 2012). Interestingly, ZNRF3 has recently been found mutated in 
HCC, meanwhile RNF43 is the only WNT pathway-related gene found mutated in CC 
so far (Schulze et al. 2015; Ong et al. 2012; Talabnin et al. 2016). 
To inactivate RNF43 and ZNRF3, gRNAs were designed to target a region before the 
functional RING domain, responsible for Frizzled ubiquitination and degradation. As 
previously described, cells were transfected with plasmids containing gRNAs, Cas9 
and GFP reporter and then were sorted after 48h. Clonally expanding cells were 
isolated and maintained as separate cultures. I have generated a total of 20 organoid 
lines that I have then used to select for positive R&Z mutations. 
I hypothesized that R&Z mutant liver organoids would survive R-spondin1 withdrawal, 
similar to R&Z mutated intestinal organoids which are reported to survive in culture 
without this essential growth factor (Koo et al. 2012). Strikingly, three lines were 
	
Figure 4.5. TP53 mutated organoids have altered gene expression of differentiation markers. 
qRT-PCR expression analysis for ductal and hepatocytes markers in mutant clones hT-/if-1 and hT-/--2 
and healthy organoids. Data represent mean ± SEM.	
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resistant to the restricted media conditions and could be expanded for several 
passages (Figure 4.6a, b, c). The remaining 17 lines died after 2-3 passaging in 
absence of R-spondin1, suggesting that they were not mutant for R&Z (Figure 4.6a).  
As expected, the three resistant lines (hRZ-1, hRZ-2 and hRZ-3) were found to be 
mutated in both genes after performing Sanger sequencing analysis (Figure 4.6d). 
Specifically, hRZ-2 and hRZ-3 had frameshift mutations in both genes (hR-/-Z-/--2, hR-
/-Z-/--3), while hRZ-1 had an in-frame mutation in one of the ZNRF3 alleles and 
	
Figure 4.6. R&Z mutated organoids resist R-spondin1 withdrawal and are sensitive to porcupine 
inhibition. a) Transfected clones were selected by removal of the growth factor R-spondin1. Graph 
shows survival of the mutant clones after several passaging. b)  Brightfield pictures showing R-spondin1 
withdrawal resistance of mutated clones. Scale bar, 1mm. c) Graph showing organoid formation 
efficiency in normal condition, R-spondin1 withdrawal and IWP2 (3µm) treated cultures. Experiment was 
performed twice. Data represent mean ± SEM. d) DNA sequence of mutated clones. RED, PAM 
sequence; BLUE, gRNA target sequence; ORANGE, insertion; -, deletion; Ref, reference; h, human; R, 
RNF43; Z, ZNRF3; ins, insertion; del, deletion.  
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frameshift mutations in the other alleles (hR-/-Zif/--1). Unfortunately, hR-/-Z-/--2 and hR-/-
Z-/--3 stopped expanding when they reached passage 10, while hR-/-Zif/--1 was still 
proliferating and has been expanded up to 19 passages (Figure 4.6a). For this reason, 
also in this case it has not been always possible to repeat the experiments and to 
confirm the results observed. 
To further confirm functional inactivation of R&Z in hR-/-Zif/--1, I have performed an 
organoid formation assay by dissociating the culture to single cells, culturing them in 
different conditions and quantifying the number of growing organoids (Figure 4.6c). As 
expected, I observed no difference in organoid formation efficiency in the mutant clone 
with or without R-spondin1 (~7%). On the other hand, the organoid formation efficiency 
of healthy organoids (parental line not subjected to the engineering procedure) 
dropped to 0% in absence of R-spondin1 as previously reported (Huch et al. 2014). 
Expectedly, when the porcupine inhibitor IWP2 (that prevents WNT secretion, thus 
inhibiting the WNT pathway activation) was added to the media, organoid formation 
efficiency plummeted in both cases, suggesting that R&Z mutant organoids still need 
a WNT ligand source in order to survive. 
At microscopic evaluation, I could not observe any significant difference between the 
mutated cultures and healthy organoids. Similarly, both healthy and mutated organoids 
presented a one layer cyst-like structures when stained with H&E and did not show 
any abnormalities (Figure 4.7). This suggests that mutating R&Z alone it is not enough 
to induce tumour-like changes at histological level. 
 
To further confirm that R&Z inactivation results in WNT pathway activation, I have 
performed RNA analysis of common WNT target genes. AXIN2 was upregulated in 
	
Figure 4.7. R&Z mutated organoids do not present histologic alterations. Representative pictures 
H&E staining of formalin-fixed paraffin-embedded organoids. Scale bar, 100µm.	
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both hR-/-Z-/if-1 and hR-/-Z-/--2, whereas LGR5 was upregulated only in hR-/-Z-/--2, 
suggesting that both ZNRF3 alleles are required to be inactivated to fully trigger WNT 
pathway activation in human organoid cultures (Figure 4.8). Interestingly, I have also 
observed an increase in both ductal and hepatocytes markers, suggesting that R&Z 
might somehow also play a role in maintaining the differentiation status of the culture 
(Figure 4.8). Further investigations, including testing the ability of R&Z mutated 
cultures to differentiate into functional hepatocytes, will help to test this hypothesis. 
 
	
4.4 R&Z and TP53 mutations combined induce a tumoroid-like 
phenotype in human liver organoids  
As demonstrated in section 4.2, TP53 mutated organoids acquire features of malignant 
transformation, whereas R&Z mutations induce WNT pathway activation in organoid 
cultures. These data suggest that while mutations in TP53 could act as driver mutations 
in cancer, R&Z cannot. To investigate whether R&Z could have a role in promoting 
tumour progression, I have decided to generate human liver organoid cultures carrying 
mutations in both TP53 and R&Z. 
Cells were transfected with three plasmids containing gRNA for RNF43, ZNRF3 and 
TP53 together with Cas9 and then sorted for GFP fluorescence after 48h. Once again, 
clones were selected by adding Nutlin3 to media condition right after sorting, allowing 
growth of only TP53 mutated cells. A total of 16 resistant clones were isolated and 
expanded. Sanger sequencing analysis revealed presence of mutations predicted to 
inactivate all three genes in 4 different clones (Figure 4.9). 
	
Figure 4.8. R&Z mutated organoids show WNT pathway activation and altered gene expression 
of differentiation markers. qRT-PCR expression analysis for Wnt target genes and ductal and 
hepatocytes markers in R&Z mutant cultures and healthy organoids. Data represent mean ± SEM.	
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Figure 4.9. DNA sequence of TP53 and R&Z triple mutant clones. RED, PAM sequence; BLUE, 
gRNA target sequence; ORANGE, insertion; -, deletion; Ref, reference; h, human; T, TP53; R, RNF43; 
Z, ZNRF3; ins, insertion; del, deletion.  
 
Figure 4.10. TP53 and R&Z triple mutant clones are aneuploid. Ploidy analysis of mutant organoid 
cultures. Graph indicates the % of chromosomes counts present in each sample. Results are expressed 
as % of ploidy per number of metaphases counted (Healthy_O, n=15; hT-/-R-/-Z-/--1, n=20; hT-/-R-/-Z-/--2, 
n=27; hTif/ifR-/-Z-/--3, n=23; hT-/-R-/-Z-/if-4, n=20). 
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To test for abnormalities in chromosome numbers, I have performed karyotype 
analysis. Expectedly, aneuploidy was found in all clones analyzed. Interestingly, one 
clone, hTif/ifR-/-Z-/--3, exhibited more than 90% of chromosomal gains (Figure 4.10). 
At microscopic observation, some organoids presented as darker, more compact 
structures or enlargement of the outer cell layer (Figure 4.11), resembling what we had 
previously observed with the patients-derived tumoroids. For example, hT-/-R-/-Z-/--1 
and hT-/-R-/-Z-/--2 presented pseudoglandular-like structures also observed in HCC-
derived tumoroids, whereas hTif/ifR-/-Z-/--3 exhibited general thickening and abnormal 
architecture.  
Overall, this data suggests that although mutations in TP53 alone are able to induce 
both chromosomal abnormalities and histologic changes to normal organoids, further 
mutations might be needed to achieve a tumoroid-like state. In addition, R&Z mutations 
seem to be able to further push towards a tumoroid-like phenotype (darker, more 
compact structures), suggesting a possible role for R&Z in promoting liver cancer 
progression. 
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Figure 4.11. TP53 and R&Z triple mutant clones show tumoroid-like features. Representative 
brightfield microscopy images (left column) and H&E histological analysis (middle column) of the 
CRISPR-mutated organoid lines. Scale bar, 100µm. Note difference between Healthy_O and mutated 
cultures.	
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5. RESULTS PART III 
 
The role of RNF43 and ZNRF3 in adult 
liver homeostasis and repair 
 
5.1 Summary 
RNF43 and ZNRF3 (from here on called R&Z) promote negative regulation of the Wnt 
pathway by controlling the level of Frizzled on the cell surface. Interestingly they have 
been found to act as tumour suppressors in the mouse intestine, inducing adenoma 
formation after few weeks from the deletion (Koo et al. 2012). Of note, R&Z have been 
found to be mutated in several cancer types, including HCC and CC (Guichard et al. 
2012; Ong et al. 2012), but their role in liver cancer (or physiology) have not been fully 
explored yet. Only recently, after R&Z global deletion from the adult mice, they have 
been suggested to be important in regulating liver metabolic zonation (Planas-Paz et 
al. 2016). 
In this section, I investigate the role of R&Z in the liver by specifically deleting the two 
genes in either adult hepatocytes or biliary ducts. Firstly, I have analysed and showed 
the R&Z are both expressed in the liver and, more specifically, in both the hepatocyte 
and cholangiocyte compartments.  
Upon R&Z deletion in ductal compartment using a Sox9CreERT2 line, I observed no 
significant difference between deleted and non-deleted livers both in normal conditions 
or when mice were fed a DDC diet, known for triggering ductular reaction. However, I 
have established organoid cultures from the R&Z deleted ducts and I have 
demonstrated that mouse liver organoids lacking R&Z show similar phenotype to what 
I have observed with the CRISPR-generated R&Z mutant human liver organoid, further 
validating the model system. 
When R&Z was deleted in hepatocytes, I have observed overexpression of WNT target 
genes, an increase in liver volume, fat accumulation and alteration of the metabolic 
pathways of the liver (similar to human livers affected by steatosis), suggesting a 
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possible role for R&Z in controlling liver metabolism. In addition, the histological 
features observed resemble human livers affected by non-alcoholic fatty liver disease. 
Furthermore, when livers were challenged to regenerate after a chronic damage, they 
exhibited multiple regenerative nodules and mild fibrosis already at 3 months from 
induction, while at later stages, focal nodular hyperplasia and early HCCs arose from 
the liver parenchyma.  
All together, these data suggest that although R&Z seem to not be involved in 
regulating ductular reaction, they play a role in maintaining a balanced metabolism 
during homeostasis and also are essential to promote correct regeneration following 
chronic damage.  
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5.2 R&Z are expressed in the liver during homeostasis 
First, I have analysed the expression pattern of the two genes during homeostasis in 
different liver compartments, including hepatocytes, biliary ducts, macrophages, 
endothelial cells and mouse liver organoid cultures. The strategy for collection of 
hepatocytes and non-parenchymal cells (ducts, endothelial cells and macrophages) is 
shown in Figure 5.1a, b. 
 
 
Upon RNA analysis, expression of both R&Z was detected in the total liver, 
hepatocytes, biliary ducts and at lower level in mouse liver organoids (Figure 5.2a). 
Low levels of expression of Axin2 were also found in these compartments, suggesting 
basal activation of the WNT pathway (Figure 5.2a). Of note, R&Z expression was also 
detected in sorted ductal cells. Here, Znrf3 levels were higher than Rnf43, reflecting 
the same expression pattern observed in the isolated ducts (Figure 5.2b). Conversely, 
very low expression was detected in endothelial cells and no expression was found in 
macrophages (Figure 5.2b). 
	
Figure 5.1. Diagram representing strategy for duct isolation and liver perfusion, hepatocytes 
collection and cell sorting. a) Livers were digested with collagenase and dispase solution for 3-4 hours 
until clean ducts were visible. Ducts were then isolated by picking manually under a microscope. b) 
Livers were perfused with collagenase and then mechanically dissociated. Hepatocytes were separated 
from the mixture by centrifugation at 50G. Ductal cells were labelled with anti-EpCAM antibody, 
macrophages with anti-CD11b antibody and endothelial cells with anti-CD31 antibody and then sorted. 
RNA was collected from all the isolated cell types. 
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Overall, R&Z expression can be detected in hepatocytes, isolated ducts, ductal cells 
and mouse organoids, but not in macrophages and only at very low levels in endothelial 
cells. Further analysis is needed to confirm this result and to assess the purity of the 
sorted cells and isolated ducts and hepatocytes.  
According to the expression pattern of R&Z in the liver, I sought to investigate the role 
of the two genes in this tissue by conditionally deleting them in either hepatocytes 
(AlbCreERT2) or bile ducts (Sox9CreERT2). The AlbCreERT2 allele (Schuler et al. 
2004) will drive the deletion of the genes of interest specifically in albumin-expressing 
cells, the hepatocytes. Once CreERT2 is expressed, translocation into the nucleus is 
achieved by tamoxifen (injected intra-peritoneal). This system is different from the 
AlbCre allele, in which the Cre is constitutively active and drive recombination already 
in the embryo and in hepatoblasts, which give rise to both hepatocytes and 
cholangiocytes in the adult. On the other hand, using a Sox9CreERT2 allele (Kopp et 
al. 2011), deletion will be introduced in all cells expressing Sox9 after tamoxifen 
injections. Of note, Sox9 is expressed not only in the ducts form the liver, but also in 
	
Figure 5.2. R&Z expression in liver compartments. a) qRT-PCR expression analysis or Rnf43, Znrf3 
and the WNT target gene Axin2 in total liver, hepatocytes, ducts and mouse liver organoids. Data 
represent mean ± SEM. n=2 mice/samples per group. b) qRT-PCR expression analysis or Rnf43 and 
Znrf3 in sorted ductal cells (EpCAM+), endothelial cells (CD31+) and macrophages (CD11b+). Data 
represent mean ± SEM. n=1 mouse per group.	
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the extra-hepatic and pancreas bile ducts. Furthermore, expression of Sox9 is also 
present in the stomach gland, the intestinal crypts and other tissues. Thus, using this 
allele will not provide an intra-hepatic bile duct specific model. 
 
5.1 R&Z-specific deletion in Sox9 expressing cells does not 
affect liver regeneration after DDC-induced damage  
RNF43 has been found frequently mutated in CC, subtype of PLC thought to arise 
mainly from the ductal compartment of the liver (Ong et al. 2012; Jusakul, Kongpetch, 
and Teh 2015). Importantly, ductal cells have been shown to have a role during liver 
regeneration, especially when hepatocytes proliferation is impaired (Lu et al. 2015; 
Huch, Dorrell, et al. 2013). So, to assess whether R&Z might have a role in 
regeneration or in promoting cancer formation starting from biliary ducts, I have 
decided to induce deletion of the two genes in the ductal compartment of the liver. 
Conditional knock-out mice (R&Zflox) carrying the floxed alleles of R&Z were already 
available in the lab (Koo et al. 2012). R&Zflox alleles were designed to have loxP sites 
flanking either one (Znrf3) or two (Rnf43) of the exons expressing the functional RING 
domain of the proteins (Figure 5.3a). Mice expressing the CreERT2 protein under the 
Sox9 promoter (Sox9CreERT2) were crossed with the R&Zflox mice to generate 
Sox9CreERT2-R&Zflox compound mice (Figure 5.3b). To study the role of R&Z during 
both regeneration and cancer initiation, I also decided to treat mice with a DDC diet, 
known to induce liver and bile duct injury and also to trigger a ductular reaction 
(Preisegger et al. 1999; Fickert et al. 2007). 
Experiment plan for Sox9CreERT2 driven deletion is shown in Figure 5.3b, c. When 
mice were 7-week old, they were injected with tamoxifen multiple times to efficiently 
drive deletion of the two genes of interest. Tamoxifen allows translocation of the 
CreERT2 protein in the nucleus that in turn drives excision of the loxP flanked RING 
domains of R&Z, leading to the expression of deleted non-functional proteins in Sox9-
expressing cells. Of note, Sox9 is expressed by cholangiocytes but also by hybrid 
hepatocytes localised at the portal vein (Font-Burgada et al. 2015). After three 
injections, mice were either fed a DDC diet or kept on normal diet. Tamoxifen was also 
injected one last time before the end of the DDC diet treatment. Analysis of the livers 
was performed 40 days after the first injection (one month after the end of the DDC 
diet). Liver samples were dissected and pieces were collected for histology, RNA and 
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DNA analysis and duct isolations. Mice lacking the Sox9CreERT2 allele were used as 
control. 
 
No gross morphology changes were observed in any of the livers analysed (Figure 
5.4a). In addition, I did not observe any significant change in the liver to body weight 
ratio of the deleted mice compared to the non-deleted littermates (Figure 5.4b). To 
assess whether the absence of gross morphology changes was due to not efficient 
deletion of R&Z upon tamoxifen injection, I have isolated and extracted RNA from the 
ducts to perform a quantitative PCR (qRT-PCR) analysis. Primers used for the 
amplification of R&Z were annealing in the deleted region, thus allowing detection only 
of the wild-type variant. R&Z expression was decreased in the deleted livers in both 
	
Figure 5.3. Experimental plan for Sox9-driven R&Z deletion and DDC diet. a) Schematic 
representation of Rnf43 and Znrf3 floxed alleles. Grey boxed, exons; red boxes, exons deleted after 
recombination; yellow triangles, loxP sites. b) Diagrams showing experimental plan. Mice were 
generated by crossing R&Zflox mice with Sox9CreERT2 mice. After generation, mice were injected with 
tamoxifen when 7-week old to induce gene deletion. To trigger ductular reaction DDC diet was fed to 
mice for a total of 5 days. Livers were collected for analysis 1 month after the end of the DDC diet. Ducts 
were isolated to check for R&Z expression. c) Timeline of the experiment. T; Tamoxifen. 
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normal and DDC diet. Specifically, I have observed ~50% of deletion in livers that 
received normal diet and ~70% in the DDC treated ones (Figure 5.4c).  
 
In the intestine, R&Z deletion drives activation of the WNT pathway (Koo et al. 2012). 
Also, according to my human in vitro CRISPR model, R&Z deletion should have a 
similar effect in the liver. Thus, to test whether the amount of deletion observed was 
enough to drive WNT pathway activation, I have also checked the expression of Axin2. 
Interestingly, I have observed an increase in Axin2 expression in both conditions, 
suggesting possible WNT pathway activation in the ductal compartments upon R&Z 
deletion (Figure 5.4c). 
Histologic analysis revealed no structural nor architectural differences between R&Zflox 
and Sox9CreERT2-R&Zdel, as shown by H&E staining (Figure 5.5a). To evaluate 
whether R&Z deletion and DDC-induced damage would result in fibrosis, I have 
performed Sirius Red staining, which highlights collagen fibres in the tissue. Collagen 
deposition was observed at the periportal area of mice that received DDC diet but not 
in mice that were fed with normal diet, with no difference between R&Z deleted and 
	
Figure 5.4. Sox9CreERT2 efficiently delete ~50% of R&Z in liver ducts. a) Representative pictures 
of R&Zflox and Sox9CreERT2-R&Zdel livers with and without DDC diet treatment. Scale bar, 2mm. b) 
Graph showing differences in the percentage of liver to body weight ratio. n=2 mice. Data represent 
mean ± SEM. c) qRT-PCR expression analysis of Rnf43, Znrf3 and Axin2 of ducts isolated from R&Zflox 
and Sox9CreERT2-R&Zdel mice fed with normal or DDC diet. Data represent mean ± SEM. n=2 mice 
per condition. Statistic was not performed due to low sample size. 	
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wild type livers (Figure 5.5a). Finally, to assess whether R&Z deletion would trigger an 
increase in ductal cells, I performed a staining for PCK. Again, I have observed an 
increase in PCK+ cells at the periportal area in the DDC-treated mice, with no 
significant difference between deleted and undeleted R&Z (Figure 5.5a, b), however 
an increased number of samples need to be analysed in order to confirm this 
observation. 
 
Overall, these data suggest that although R&Z deletion can drive overexpression of 
Axin2 in the duct compartment, it does not affect injury response to DDC diet-induced 
damage in this model. A new approach that would allow for complete deletion of R&Z 
	
Figure 5.5. R&Z deletion in ducts does not affect liver injury repair after DDC treatment. a) 
Representative pictures of H&E and Sirius Red staining and immunostaining for PCK of R&Zflox and 
Sox9CreERT2-R&Zdel liver sections with or without DDC diet treatment. Scale bar, 100µm (H&E, Sirius 
Red) and 50µm (PCK). b) Quantification of PCK+ cells per PV. Graphs represent distribution of cells per 
PV counted. White circles represent outliners. Bars represent quartile percentile (top is 75% and bottom 
is 25%). Median is represented as a horizontal line in the bars. PV, portal vein.	
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in the ductal compartment is needed in order to rule out the role of these two genes in 
regulating ductular reaction. For this reason, I have decided to not focus on this model. 
 
5.2 Sox9CreERT2-R&Zdel derived organoids exhibit WNT 
pathway activation 
As mentioned in the introduction, liver organoid cultures originate from the ductal 
compartment of the liver (Huch, Dorrell, et al. 2013; Huch et al. 2014). For this reason, 
I hypothesized that organoids originated from Sox9CreERT2-R&Zdel mice would also 
show deletion of R&Z and thus reduction in their expression. As R&Z deletion in the 
biliary ducts did not show any significant phenotype, I decided to establish organoids 
from both R&Zflox and Sox9CreERT2-R&Zdel mice and use this to validate what I have 
previously observed in the R&Z-mutated human liver organoids. According to my 
previous data, R&Z mutant human liver organoids can grow in absence of R-spondin1 
(RSPO1), whereas WT organoids cannot. Thus, to ensure the growth of organoids 
originated only from R&Z deleted cells, I have seeded cells in media lacking RSPO1. 
Once organoids were formed, I hand-picked two growing clones, thus generating two 
independent lines. Organoids derived from non-deleted R&Zflox mice were instead 
cultured in isolation media. 
To confirm deletion of R&Z, I have performed qRT-PCR analysis on RNA collected 
from organoid cultured in complete media (CM) or in media lacking RSPO1 (-R). Of 
note, no expression of either Rnf43 nor Znrf3 was detected in the two clones derived 
from Sox9CreERT2-R&Zdel mice, cultured either with or without RSPO1 (Figure 5.6a). 
Whereas, R&Z were both expressed in the wild-type organoids derived from R&Zflox 
mice and partial reduction in expression was observed when cultured without RSPO1, 
in line with the decreased WNT pathway activity in absence of this growth factor (Figure 
5.6a). Furthermore, I have also detected Axin2 overexpression in both deleted clones 
(Figure 5.6a). Interestingly, the expression of Axin2 was not affected by the removal of 
RSPO1 from the media condition in the two deleted clones, although it was no longer 
detectable in the R&Zflox organoids. 
To further confirm the phenotype observed, I have performed an organoid formation 
efficiency experiment in different media conditions. Organoids were dissociated and 
cultured 500 cell/well in complete media (CM), media lacking RSPO1 (-R), media 
lacking RSPO1 and with the addition of the porcupine inhibitor IWP2 (-R+I) and finally 
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media lacking RSPO1 and containing both IWP2 and the GSK3β inhibitor CHIR-99021 
(-R+I+CHI). Analysis was performed one week after the seeding. In line with my 
previous observations, R&Z deleted organoids resisted the withdrawal of RSPO1 from 
the media and showed a similar organoid formation efficiency regardless of the 
presence of RSPO1 in the medium (Figure 5.6b, c). Expectedly, the efficiency dropped 
once WNT production was inhibited by IWP2 treatment (-R+I) (Figure 5.6b, c). Finally, 
this reduction was partially rescued by activating the pathway downstream with CHIR-
99021 (-R+I+CHI) (Figure 5.6b, c). Similar pattern was observed in the non-deleted 
organoids, apart from the -R condition, where the efficiency of organoid formation was 
reduced, although large organoids could still be observed (Figure 5.6b, c). 
 
	
Figure 5.6. R&Z mutated mouse organoids have WNT activation and resist RSPO1 withdrawal. 
a) qRT-PCR expression analysis of RN43, Znrf3 and Axin2 in R&Zflox and Sox9CreERT2-R&Zdel derived 
organoids cultured with or without RSPO1ndin1. Data represent mean ± SEM. Experiment was repeated 
twice. b, c) Organoid formation efficiency of in R&Zflox and Sox9CreERT2-R&Zdel derived organoids in 
different conditions. CM, complete media; R, R-spondin1; P, IWP2 3um (porcupine inhibitor); CHI, 
CHIR-99021. Scale bar; 2mm. Experiment was performed twice. c) Quantification of organoid formation 
efficiency. 
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Overall, these data suggest that it is possible to derive organoids lacking R&Z from 
Sox9CreERT2-R&Zdel mice. More importantly, the R&Z deleted organoids present the 
same features observed in the R&Z mutated human liver organoids, including Axin2 
overexpression, RSPO1 withdrawal insensitivity and WNT dependency. However, an 
increased number of samples is needed in order to assess whether these results are 
statistically significant. 
 
5.3 R&Z KO in hepatocytes induces increased proliferation and 
expanded GS staining. 
As ZNRF3 is also found mutated in HCC (Guichard et al. 2012), I wondered what would 
be the role of R&Z in the hepatocyte compartment. Therefore, I proceeded to generate 
a mouse model to conditionally delete the two genes in the hepatocytes. To this 
purpose, I have crossed the R&Zflox line with mice expressing the CreERT2 protein 
under the albumin promoter (AlbCreERT2) to generate AlbCreERT2-R&Zflox 
compound mice (Figure 5.7b). Tamoxifen was administrated to mice intraperitoneally 
when they were 7-week old. Upon deletion, livers were harvested for analysis after 3 
months (Figure 5.7c). Mice lacking the AlbCreERT2 allele were used as control. 
 
To assess whether R&Z were deleted after tamoxifen injection, I have extracted RNA 
from the livers and used it for qRT-PCR analysis. In all cases, deletion efficiency was 
near 100% (Figure 5.8a). To assess whether this deletion would result in Wnt pathway 
activation as observed in the previous model, I have performed qRT-PCR analysis of 
common WNT target genes. Expectedly, I have observed overexpression of Axin2, 
	
Figure 5.7. Experimental plan for hepatocyte-specific deletion of R&Z. Diagrams showing 
experimental plan. Mice were generated by crossing R&Zflox mice with AlbCreERT2 mice. After 
generation, mice were injected with tamoxifen when 7-week old (0M) to induce gene deletion and livers 
were collected for analysis 3 months (3M) after induction.  
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Lgr5 and Sp5, suggesting WNT pathway activation and further confirming my previous 
observation (Figure 5.8a).  
Macroscopic analysis of the livers revealed no gross morphological changes (Figure 
5.8b). Also, no significant difference was observed in the liver to body weight ratio in 
the R&Z deleted livers when compare to littermate controls, 3 months after inducing 
the deletion (Figure 5.8c). 
 
Histopathologic analysis revealed that liver tissues did not present any structural 
abnormalities at 3 months after R&Z deletion when compared to littermate controls 
(Figure 5.9a). A recent paper has shown that upon deleting R&Z using a R26CreERT2 
line, that induce deletion in the whole body, livers show an increase of staining for 
glutamate synthetase (GS) and Ki67, 10 days after induction (Planas-Paz et al. 2016). 
GS is a metabolic and liver-specific WNT target gene, usually expressed only in 1-2 
layers of hepatocytes in zone 3 around the CV, source for WNTs (Gebhardt 2014). To 
confirm that this was true also in my model and at longer periods after induction, I have 
then performed staining of both GS and Ki67.  
	
Figure 5.8 R&Z hepatocyte-specific deletion results in WNT target genes overexpression. a) qRT-
PCR expression analysis or Rnf43 and Znrf3 and the WNT target genes Axin2, Lgr5 and Sp5 in R&Zflox 
and AlbCreERT2-R&Zdel mice. Data represent mean ± SEM. n=2 mice per group. b) Pictures of R&Zflox 
and AlbCreERT2-R&Zdel livers. c) Graph showing differences in the percentage of liver to body weight 
ratio. n=2 mice (R&Zflox), 4 mice (AlbCreERT2-R&Zdel). Data represent mean ± SEM. ns, not significant; 
two-tail t-test was used. 
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Consistent with Planas-Paz et al., I have observed an increased GS stained area. 
Here, 5 to 16 layers of hepatocytes were stained with this marker, in contrast to the 1 
to 2 layers in the control mice (Figure 5.9a). A 3-fold expansion of GS staining around 
the CV was observed (Figure 5.9b). This increase in GS confirms WNT pathway 
activation upon R&Z deletion and suggests a potential role for R&Z in controlling 
metabolic liver zonation, like previously reported and similar to Apc mutant mice 
(Benhamouche et al. 2006; Planas-Paz et al. 2016). In addition to this, R&Z deleted 
livers exhibited a significant 4-fold increase in proliferative cells when compared to non-
deleted littermate controls, also confirming what observed by Planas-Paz et al. 10 days 
after R&Z deletion (Figure 5.9a, c). 
Overall, deletion of R&Z in hepatocytes leads to WNT pathway activation and higher 
proliferation rate. More importantly, this data show that R&Z play a role in controlling 
liver metabolic zonation, as shown by increased GS. 
 
	
Figure 5.9 R&Z hepatocyte-specific deletion causes increase in GS staining area and in Ki67 
positive cells. a) Representative H&E and immunostaining for GS and Ki67 of R&Zflox and 
AlbCreERT2-R&Zdel liver sections. Scale bar, 100µm (H&E), 500µm (GS) and 50µm (Ki67). b) 
Quantification of GS positive staining localised around central veins. n=3 mice per group. c) 
Quantification of Ki67 positive hepatocytes. n=3 mice per group. Data represent mean ± SEM; *P<0.05, 
**P<0.01, *P<0.001; two-tail t-test was used. 
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5.4 Hepatocyte-specific R&Z deletion results in metabolic 
alterations similar to human livers affected by steatosis 
The increase in GS staining observed above suggested a role for R&Z in controlling 
liver metabolism. For this reason, I decided to investigate what other metabolic 
changes happen in the liver upon R&Z deletion. To this purpose, I have analysed the 
expression of several genes involved in multiple metabolic pathways of the liver (Figure 
5.10). 
 
Of note, I have observed an increase in the expression of Cyp7a1, Acot4, Cyp2c39, 
Fgf21, Acaa2, Fads2, Aqp9 involved in metabolic processes like beta oxidation, 
ketogenesis and fatty acid metabolism (Figure 5.10). These data suggest that R&Z 
might be important in keeping a balanced metabolism in the liver and that their 
alteration can cause increased expression of enzymes involved in several metabolic 
	
Figure 5.10. R&Z hepatocyte-specific deletion induce partial metabolic changes at 
transcriptional level. RT-qPCR expression analysis of genes involved in fatty acid metabolism, beta 
oxidation, ketogenesis and cholesterol metabolism and others of R&Zflox control mice and AlbCreERT2-
R&Zdel mice. n=5 mice (R&Zflox) and 5 or 6 mice (AlbCreERT2-R&Zdel). Results represent single events 
± SD. two-tail t-test and Holm-Bonferroni correction were used for statistical analysis, data are not 
significant. 
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pathways, in agreement with the results published for the TCF4 KO mice, where these 
genes are downregulated. However, due to high variability between the samples, data 
are not significant and an increase number of samples need to be tested in order to 
confirm this observation. 
As the changes observed relate to fat metabolism, I sought to explore what are the 
changes in gene expression observed in human livers presenting pathologies related 
to fat metabolism alteration. With the help of Mikel McKie, I have analysed the gene 
expression profile of a cohort of patients affected by steatosis or non-alcoholic 
steatohepatitis (NASH) published by Arendt et al. 2015. Interestingly, livers affected by 
steatosis and NASH had a significantly higher expression of the ligand WNT5A and 
the WNT target genes AXIN2 and LGR5, suggesting possible activation of the WNT 
pathway in these samples. Furthermore, steatotic and NASH livers exhibited a 
significant increased expression of metabolic genes like CYP7A1 and FADS2, also 
upregulated after R&Z deletion. Whereas, AKR1B10 was upregulated only in NASH 
and not in steatosis and ACOT4 was significantly over expressed only during steatosis. 
Expression pattern similar to the steatosis one (no change in Akr1b10 and increase in 
Acot4) was observed in R&Z deleted livers. 
Overall this data indicates that human livers affected by steatosis and NASH exhibit 
activation of the WNT pathway similar to R&Z deleted livers. In addition, there is a 
correlation between the increased expression of metabolic genes observed in human 
livers affected by steatosis and mouse R&Z deleted livers. This data suggests that the 
altered metabolic expression profile observed in the R&Z deleted livers might lead to 
steatosis after long-term deletion. 
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5.5 Hepatocyte-specific R&Z deletion upon acute and chronic 
liver damage 
Liver cancer most commonly arises upon liver damage due to viral infections, chronic 
diseases and excessive alcohol intake, among others (El-Serag and Rudolph 2007). 
Specifically, 80 to 90% of hepatocellular carcinomas arise as a consequence of chronic 
liver damage. For this reason, and also to study the role of R&Z during regeneration, I 
sought to investigate the effect of their deletion in the liver in vivo after acute and 
chronic damage.  
	
Figure 5.11. Steatosis and NASH expression profiling. Expression of WNT related genes and 
metabolic genes in a cohort of liver from healthy donors and patients with steatosis and NASH. n=24 
(healthy control), 20 (steatosis), 19 (NASH). Results represent single events ± SD. *P<0.05; **P<0.01; 
***P<0.001; two-tail t-test and Holm-Bonferroni correction were used. Data were obtained from Arendt 
et al. 2015. 
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To induce liver damage, I have treated mice with carbon tetrachloride (CCl4). CCl4 is 
a known toxic agent that induces death in the hepatocytes surrounding the central 
veins, thus triggering hepatocytes proliferation and a ductal progenitor response to 
help regenerate the liver (Beer et al. 2008). In the acute damage (AD) model, CCl4 
was injected in single dose; whereas for the chronic damage (CD) model CCl4 was 
injected in lower dose but multiple times over a period of six weeks. 
 
5.5.1 Hepatocyte-specific R&Z deletion does not affect liver regeneration 
upon acute damage 
In the acute damage model, mice were first injected with tamoxifen to drive R&Z 
deletion and, after two days, CCl4 was administered intraperitoneally at high dose 
(1ml/kg). Also, tamoxifen was injected again after two days to induce deletion in newly 
formed hepatocytes generated from non-deleted progenitors. Livers were analysed 3 
months after the first injection (Figure 5.12a, b).  
 
Upon RNA analysis, complete deletion of both R&Z in all livers analysed was confirmed 
(Figure 5.13a). In addition, I have also confirmed over expression of the WNT target 
genes Lgr5 and Axin2, similar to what I had previously observed (Figure 5.13a). Of 
note, no liver gross morphology abnormalities were observed (Figure 5.13b). Liver to 
body weight ratio was increased by ~67% in R&Z deleted and damaged mice 
compared to non-deleted but damaged controls (Figure 5.13c). This was in contrast 
with the undamaged R&Z deleted livers, where I had observed no significant difference 
	
Figure 5.12. Experimental plan for hepatocyte-specific deletion of R&Z and acute damage. a) 
Diagrams showing experiment plan. Mice were injected with tamoxifen when 7-week old, with CCl4 2 
days later and tamoxifen again after 2 days. Livers were collected for analysis 3 months after induction. 
b) Timeline of the experiment. T, tamoxifen; C, CCl4.	
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on the liver to body weight ratio between R&Z deleted and non-deleted livers, 
suggesting that damaging the liver might results in a hyperplastic phenotype (Figure 
5.13c). 
 
At histological level, livers were not showing any structural alterations and the pattern 
of GS staining was very similar to what I had previously described for the R&Z KO non-
damaged model, with ~50% of staining around the CV (Figure 5.14a, b). In addition, I 
also observed an increase in proliferative cells similar to the undamaged livers at the 
same time point (Figure 5.14a, c). 
	
Figure 5.13. R&Z hepatocyte-specific deletion results in WNT target genes overexpression and 
hyperplasia. a) qRT-PCR expression analysis or Rnf43 and Znrf3 and the WNT target genes Axin2 
and Lgr5 in R&Zflox and AlbCreERT2-R&Zdel mice. Data represent mean ± SEM. n=2 mice (R&Z) and 1 
mouse (Axin2 and Lgr5). b) Pictures of R&Zflox and AlbCreERT2-R&Zdel livers. c) Graph showing 
differences in the percentage of liver to body weight ratio. n=3 mice (R&Zflox) and 4 mice (AlbCreERT2-
R&Zdel). Data represent mean ± SEM. *P<0.05; two-tail t-test was used. 
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Overall, when challenged by CCl4-induced AD, livers lacking R&Z are able to 
regenerate without presenting structural alterations. Of note, livers exhibit the same 
characteristic observed in absence of AD, including activation of the WNT pathway and 
increased rate of proliferative cells. Of note, a hyperplastic phenotype was observed, 
although no histological differences were detected when compare to control mice. 
Considering these preliminary data, I decided to no longer focus on the AD model and 
therefore no more livers were analysed. 
 
 
 
	
Figure 5.14. R&Z hepatocyte-specific deletion does not affect liver regeneration following acute 
damage.  a) Representative pictures of H&E and immunostaining for GS and Ki67 of R&Zflox and 
AlbCreERT2-R&Zdel damaged liver sections. Scale bar is 100um for H&E, 500um for GS, 50um for Ki67. 
Arrowhead, Ki67+ cells. b) Quantification of GS positive staining localised around central veins. n=2 
mice per group. c) Quantification of Ki67 positive hepatocytes. n=1 mouse (R&Zflox) and 2 mice 
(AlbCreERT2-R&Zdel). Data represent mean ± SEM. Statistic not performed due to low sample size. 
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5.5.2 Hepatocyte-specific R&Z deletion induces formation of regenerative 
nodules and mild fibrosis upon chronic damage 
As previously mentioned, chronic liver diseases precede HCC establishment in most 
of the cases. Therefore, to better recapitulate what happens in the human before 
tumours arise, I also investigated the role of R&Z upon chronic damage (CD). 
Mice were injected with tamoxifen to conditionally delete R&Z when they were 7-week 
old. After that, to induce CD mice were injected with CCl4 for a total of 6 weeks. During 
this period, mice were also injected with tamoxifen two more times the first 2 weeks 
and one last time at the end of the protocol, to induce R&Z deletion in potentially newly 
formed hepatocytes originated from liver progenitors (Figure 5.15a). Livers were 
collected for analysis 3 months after the beginning of the protocol (Figure 5.15b).  
 
Upon RNA collection from the total livers, qRT-PCR analysis revealed a reduction in 
R&Z expression of about 80%, in stark contrast to my previous observation in the 
undamaged (UD) and AD models where complete deletion was observed. This data 
suggests that, after the chronic damage, newly formed liver cells (hepatocytes and 
non-parenchymal cells) had been derived from cells carrying undeleted copies of R&Z 
(Figure 5.16a). Overexpression of the WNT target gene Axin2, but not Lgr5 and Sp5, 
was still present, indicating that complete deletion of R&Z is needed to fully activate 
the pathway (Figure 5.16b).  
	
Figure 5.15. Experimental plan for hepatocyte-specific deletion of R&Z and chronic damage. a) 
Diagrams showing experiment plan. Mice were injected for the first time with tamoxifen when 7-week 
old, the injected again multiple times with CCl4 and tamoxifen. Livers were collected for analysis 3 
months after induction. b) Timeline of the experiment. T, tamoxifen; C, CCl4.	
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At macroscopic observation, livers were visually larger and exhibited irregular nodular 
surface (Figure 5.16c). In addition, analysis of the liver to body weight ratio revealed 
an increase of ~60%, similar to the AD model but in contrast to undamaged mice, 
where no change was observed (Figure 5.16d). These data suggest that CD is able to 
induce liver hyperplasia upon R&Z deletion. 
The histopathological analysis revealed that livers exhibited tissue damage and 
presence of multiple small nodules, as confirmed by H&E staining (Figure 5.17a). 
These structures exhibited cells with small nuclei and low nucleus to cytoplasm ratio. 
Interestingly, immunological infiltrate (lymphocytes and macrophages) and large liver 
cell changes (giant hepatocytes), usually associated with aging, cirrhosis and/or 
neoplasia (Park and Roncalli n.d.), were present in these livers, especially in the 
perinodular area (Figure 5.17a). Considering the histological features of these small 
nodules and after pathological evaluation by consultant histopathologist Dr. Susan 
	
Figure 5.16. In the setting of chronic damage, R&Z deletion induces gross morphology changes, 
Axin2 overexpression and hyperplasia in R&Z deleted livers. a) qRT-PCR expression analysis of 
Rnf43 and Znrf3 in R&Zflox and AlbCreERT2-R&Zdel livers with and without CD. Data represent mean ± 
SEM. n=4 mice per group. b) qRT-PCR expression analysis of the WNT target genes Axin2, Lgr5 and 
Sp5 in R&Zflox and AlbCreERT2-R&Zdel livers. Data represent mean ± SEM. n=2 mice per group.c) 
Pictures of R&Zflox and AlbCreERT2-R&Zdel livers. Magnification show nodular liver surface. d) Graph 
showing differences in the percentage of liver to body weight ratio. n=2 mice (R&Zflox UD), 3 mice (R&Zflox 
CD),4 mice (AlbCreERT2-R&Zdel UD and CD). Data represent mean ± SEM. *P<0.05; ns, not significant; 
two-tail t-test was used. ND, not detected; UD, undamaged; CD, chronic damage.	
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Davies, these were classified as regenerative nodules. Of note, control livers 
chronically damaged but WT for R&Z did not present any of the alterations described 
above and were fully regenerated at the time of the analysis.  
Increased GS staining around the CV further confirmed activation of the WNT pathway 
also in this case. Occasionally, GS staining was extending from zone 3 up to zone 1 
(around the PV), in stark contrast to undamaged R&Z mutant littermates of the same 
age, where zone 1 is negative for GS marker (Figure 5.17a, b).  Similarly, there was a 
significant increase of ~9 fold in proliferative hepatocyte cells in the KO livers but not 
in the WT ones, as confirmed by Ki67 staining (Figure 5.17a, c). 
Considering the histological observations in the chronically damaged livers, I thought 
to investigate whether the failed regeneration would result in deposition of collagen 
fibres and thus fibrosis due to cell death. To this purpose, I performed a Sirius Red 
staining that highlights collagen fibres located in the tissue. Interestingly, I have 
observed deposition of few laces of collagen only in the R&Z chronically damaged 
livers (Figure 5.17a). In line with the previous findings, this mild fibrosis was located 
mainly at the perinodular regions, where the most amount of tissue damage was 
observed. 
Overall, deletion of R&Z specifically in the hepatocyte compartment results in impaired 
regenerative potential of the liver. Cells are unable to repopulate the tissue with 
functional new hepatocytes, probably because they fail to fully activate or complete the 
regenerative program, thus resulting in formation of regenerative nodules, hepatocytes 
proliferation and collagen deposition in the tissue. 
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Figure 5.17. In the setting of chronic damage, liver-specific R&Z deletion induces regenerative 
nodules formation, increase proliferation and mild fibrosis in the liver. a) Representative pictures 
of H&E and Sirius Red staining and immunostaining for GS and Ki67 of chronically damaged R&Zflox 
and damaged and undamaged AlbCreERT2-R&Zdel liver sections. Scale bar, 100µm (H&E), 500µm 
(GS, Sirius Red) and 50µm (Ki67). The white dotted circle marks the nodule border. Perinodular area is 
right outside of the circle. b) Quantification of GS positive staining localised around central veins. n=3 
mice per group. c) Quantification of Ki67 positive hepatocytes. n=3 mice per group. Data represent 
mean ± SEM; *P<0.05, **P<0.01, ***P<0.001; two-tail t-test was used; CD, chronic damage; UD, 
undamaged. 
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5.6 Long-term hepatocyte-specific R&Z deletion in adult liver 
parenchyma induces steatohepatic injury in both 
undamaged and chronically damaged livers 
According to my data, R&Z play a role not only in controlling metabolism during 
homeostasis, but they also seem to be essential for the liver to properly regenerate 
after a chronic damage. Therefore, I asked whether the absence of R&Z from the 
hepatocytes for longer periods could further exacerbate the phenotypes observed or 
whether livers would finally recover after chronic damage. To tackle this question, I 
conditionally deleted R&Z from livers and collected the tissues after 7 months, either 
undamaged (UD) or with a chronic damage (CD) (Figure 5.18a). Upon collection, RNA 
was analysed and used to assess R&Z deletion and WNT target genes 
overexpression. Once again, deletion was total in the UD model and only partial in the 
CD model, with ~25% of expression still detectable (Figure 5.18b). Overexpression of 
Axin2, Lgr5 and Sp5 was observed in both UD and CD livers, suggesting WNT pathway 
activation (Figure 5.18c). 
Morphologically, UD and CD livers were visually larger and, the damaged ones, 
exhibited several visible nodules with heterogeneous shapes and sizes on the surface 
(Figure 5.18d). Also, a large nodule was observed on the surface of one of the control 
UD (1/5) and one of the mutant UD (1/3) mice (Figure 5.18d). Since old mice are known 
to naturally develop tumours in the liver and, considering the very low frequency of this 
event, it would be difficult to prove that the nodule on the mutant liver is a direct 
consequence of the deletion rather than due to the mouse age. For this reason, I have 
decided to not focus on this specific event. 
Although I did not observe an increase in the liver to body weight ratio in the 
undamaged R&Z deleted mice after 3 months, at the later time point both damaged 
and undamaged livers showed an increase of ~60-70%, suggesting that R&Z deletion 
eventually result in hyperplasia also during homeostasis and that this effect is not a 
direct consequence of the damage itself but it is accelerated by it (Figure 5.18e). Once 
more, this data suggests a regenerative defect of R&Z deleted livers. 
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At histopathologic analysis, both UD and CD R&Z deleted livers exhibited multiple 
small nodular foci characterized by clear cell changes and due to either fat 
accumulation or cellular degeneration (Figure 5.19Error! Reference source not 
found.a). Also, livers showed extensive cellular damage characterised by the 
presence of hepatocytes undergoing ballooning degeneration. All these pathological 
features are commonly associated to steatohepatic injury and were observed in most 
of the R&Z mutant mice analysed (3/3 for the UD mice and 7/9 for the CD mice), but 
not in control UD (0/3) or CD (0/4) mice. This data further suggested a possible role for 
R&Z in regulating liver metabolism. Furthermore, regenerative nodules were still 
observed in the CD R&Z deleted livers after 7 months, although more sparsely. 
	
Figure 5.18. Long-term deletion of R&Z induces hyperplasia and larger nodules formation on the 
liver surface after CD. a) Timeline of the experiment. T, tamoxifen; C, CCl4. b) qRT-PCR expression 
analysis of Rnf43 and Znrf3 in R&Zflox and AlbCreERT2-R&Zdel livers with and without CD after 7 months. 
Data represent mean ± SEM. n=4 mice per group. c) qRT-PCR expression analysis of the Wnt target 
genes Axin2, Lgr5 and Sp5 in R&Zflox and AlbCreERT2-R&Zdel livers. Data represent mean ± SEM. n=2 
mice per group.d) Pictures of R&Zflox and AlbCreERT2-R&Zdel livers. Arrowheads, larger nodules visible 
on liver surface. e) Graph showing differences in the percentage of liver to body weight ratio. n=4 mice 
(R&Zflox UD and CD), 3 mice (AlbCreERT2-R&Zdel UD), 9 mice (AlbCreERT2-R&Zdel CD). Data 
represent mean ± SEM. *P<0.05, **P<0.01, ***P<0.001; two-tail t-test was used. ND, not detected; UD, 
undamaged; CD, chronic damage.	
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A significant increase in both GS area staining and cell proliferation was detected in 
both UD and CD livers, with a ~3 fold increase in GS and ~9 fold increase in Ki67 
positive cells in the UD livers and slightly less in the CD ones (Figure 5.19a, b, c). To 
assess whether the damage observed would result in fibrosis, I have again performed 
Sirius red staining. No collagen deposition was observed in the undamaged liver, but 
few laces - less than at the earlier time point - were instead present in the CD model, 
suggesting an impaired recovery from the damage (Figure 5.19a). 
The characteristic features observed in the R&Z deleted UD and CD livers after 7 
months - steatohepatic injury and ballooning degeneration - highly resembles what has 
been described for human livers affected by non-alcoholic fatty liver disease (NAFLD) 
(Takahashi and Fukusato 2014). To assess whether R&Z deletion would trigger 
accumulation of fat in the hepatocytes, I have performed an Oil Red staining. 
Interestingly, sporadic foci of fat accumulation were present in both UD and CD livers 
but not in the non-deleted littermate controls (Figure 5.19a).  
Overall, deletion of R&Z in hepatocytes after 7 months leads to increase liver volume, 
higher proliferation rate and WNT pathway activation. More importantly, R&Z seems to 
play a role in controlling liver metabolism as shown by increased GS staining, the 
presence of steatohepatic nodules and fat accumulation. Extensive cellular damage 
was also observed, probably due to the steatohepatic lesions and accumulation of 
reactive oxygen species (ROS) and/or failed activation or completion of the 
regenerative mechanism. These data might indicate that R&Z play an important role in 
maintaining liver homeostasis turnover and metabolism. Also, the presence of 
regenerative nodules and the mild fibrosis still at the later time point suggest that R&Z 
are also essential to induce proper regeneration after a chronic damage. 
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Figure 5.19. Long-term deletion of R&Z induces steatohepatic foci and fat accumulation in the 
liver. a) Representative pictures of H&E, Sirius Red and Oil Red staining and immunostaining for GS 
and Ki67 of chronically damaged R&Zflox and damaged and undamaged AlbCreERT2-R&Zdel liver 
sections. Scale bar, 100µm (H&E, Oil Red), 500µm (GS, Sirius Red) and 50µm (Ki67). Arrowhead, 
ballooning degeneration. b) Quantification of GS positive staining localised around central veins. n=3 
mice per group. c) Quantification of Ki67 positive hepatocytes. n=3 mice per group. Data represent 
mean ± SEM; *P<0.05; two-tail t-test was used; CD, chronic damage; UD, undamaged. 
 
5.7 Long-term hepatocyte-specific R&Z deletion in adult liver 
parenchyma leads to early HCC and focal nodular 
hyperplasia after CD 
As previously mentioned, livers were exhibiting several significantly larger nodular 
structures after CD at the later time point (Figure 5.16c). To characterise these 
structures, nodules were dissected and divided into three parts. Material for RNA, DNA 
and histological analysis was collected from two independent nodules, found on two 
different livers.  
Histopathological analysis of the nodules, performed by histopathologist Dr. Susan 
Davies, identified these as early HCC (eHCC) or focal nodular hyperplasia (FNH) 
(Figure 5.20). eHCC were dysplastic, presenting abnormal edges that compressed the 
adjacent tissue, thus resulting in tissue dysplasia, and increased proliferative cells, as 
shown by Ki67 staining (Figure 5.20). Furthermore, CD34+ endothelial cells were also 
observed inside the nodules, suggesting increased vascularization of the nodule, 
typical feature of eHCC (Figure 5.20). Finally, cells inside the nodules were smaller 
and presented a steatohepatic phenotype (Figure 5.20). All these features are 
characteristic of eHCCs (Kudo 2013), and were used to identify eHCC presence in 6 
out of 9 of the mice analysed. On the other hand, FNH is a benign lesion thought to 
arise from abnormal blood vessels regeneration after liver damage and it is 
characterised by the presence of an extensive ductular reaction with large septa 
without pleiomorphic cellular changes (Figure 5.20) (J. Nault, Bioulac–Sage, and 
Zucman–Rossi 2013). Increased proliferation and vascularization was also present in 
these nodules (Figure 5.20). A total of 2 mice out of 9 presented FNH growth. 
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As mentioned, RNA was collected from both eHCC and FNH and the respective total 
livers, TLeHCC and TLFNH. In line with previous analysis, R&Z deletion was observed in 
both TLeHCC and TLFNH (Figure 5.21). Specifically, ~55% of deletion was observed in 
TLeHCC and almost complete deletion (~90%) in TLFNH, when compared to undeleted 
chronically damaged liver TLflox. Strikingly, no expression of either Rnf43 nor Znrf3 was 
detected in either eHCC or FNH, suggesting that either the WNT pathway was not 
active in these structures or that they had clonally originated from R&Z deleted 
hepatocytes, thus being unable to express the two genes (Figure 5.21). To investigate 
	
Figure 5.20. Long-term R&Z deletion and chronic damage promote eHCC and FNH formation. 
Representative pictures of H&E staining and immunostaining for Ki67 and CD34 of chronically damaged 
R&Zflox liver and AlbCreERT2-R&Zdel nodules sections. Scale bar, 200µm (H&E top panel), 100µm (H&E 
bottom panel) and 50µm (Ki67 and CD34). Dotted line, nodules border; arrowheads, tissue 
compression. 
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whether this result was a consequence of the WNT pathway being inactive, I have 
checked the expression of the WNT target gene Axin2 in both nodules and respective 
total livers. As expected, Axin2 was upregulated in both TLeHCC and TLFNH with a fold 
change higher than 7 in both cases (Figure 5.21). Interestingly, eHCC still exhibited a 
change fold increase of more than 4 in Axin2 expression when compared to the control, 
suggesting activation of the WNT pathway in this lesion and more importantly, that the 
nodule itself might have arisen from an R&Z deleted cell (Figure 5.21). However, Axin2 
expression in FHN was highly reduced when compared to the respective liver TLFNH 
and equal to the littermate control TLflox (Figure 5.21). In this case, WNT pathway was 
not active in the nodule, thus it cannot be discerned whether the nodule originated from 
R&Z wild type or deleted cells. At this stage, I was only able to collect one nodule of 
each type, thus further analysis of an increased number of nodules is needed in order 
to fully understand the origin of these lesions. 
 
 
Overall, these data suggest that due to the metabolic defect caused by R&Z deletion 
and/or combined with the defective regeneration after long-term chronic damage, livers 
undergo several morphological changes that eventually lead to establishment of FNH 
and/or eHCC. 
	
Figure 5.21. eHCC and FNH do not express R&Z. qRT-PCR expression analysis of Rnf43, Znrf3 and 
Axin2 in total liver from one R&Zflox+CD mouse and two AlbCreERT2-R&Zdel+CD livers with respective 
nodules. Data represent mean ± SEM. TL, total liver; eHCC, early HCC; FNH, focal nodular hyperplasya. 
Statistic was not performed due to low sample size. 
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6. DISCUSSION 
 
6.1 PLC-derived organoids as a bridging model system between 
cell lines and animal models 
Hepatocellular carcinoma (HCC) is the most frequent and most studied primary liver 
cancer (PLC), accounting for 85 to 90% of all PLCs (El-Serag and Rudolph 2007). 
Thus, it is not surprising that many HCC model systems have been already developed. 
Dozens of cell lines and animal models have been used to better our knowledge about 
this disease but, more importantly, to help us devise new therapeutic strategies. 
Despite the recent advancement in the field, treatment strategies are still scarce and 
PLC remains one of the most lethal malignancies worldwide (Pinter et al. 2016). 
Being easy and cheap to handle, cancer cell lines are commonly the first approach 
used by scientists to test the effect of newly discovered drugs. The efficiency of the 
drug Sorafenib, was indeed first tested in cancer cell lines (Liu et al. 2006). More 
recently, this anticancer drug is sometimes used as a targeted therapeutic strategy for 
HCC (Llovet et al. 2008). However, cell lines lack many of the traits that are found in 
real tumours, traits that not only include the histology and architectural organisation, 
but also the interaction between the tumour itself and the surrounding environment. 
Consequently, it is obvious that all the data gathered using cell lines will need further 
validation using a more sophisticated system, most commonly animal models. 
Unfortunately, due to the substantial limitations of cell lines in recapitulating the main 
features of the tumour, the results first gleaned from their use may be difficult to 
reproduce in an in vivo setting. These difficulties and resulting slowed progress could 
culminate in a waste of money, energy, time and animal lives. Additionally, although 
many cancer cell lines have been established for HCC, currently only two have been 
derived from cholangiocarcinoma (CC) and none from the combined HCC/CC subtype 
(CHC), two rarer forms of PLC, which account for 5-10% and 0.5-5% of all PLCs 
respectively.  
More recently, the use of patient-derived xenograft (PDX) models has allowed the 
study of human tumours in an in vivo setting, thus not only recapitulating tumour 
architecture and histology, but also the interaction with the host environment. 
Importantly, this new experimental strategy has made possible to model tumour 
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subtypes that lack established cell lines, e.g. CC (Cavalloni et al. 2016). Moreover, as 
tumours are derived directly from patients, this system has enabled the possibility of 
testing drugs for personalised treatment strategies. However, although these tumours 
have been recently shown to be able to be passaged multiple times in mice, retaining 
the tumour morphological features, their use for large scale drug screening (>20 drugs) 
has major limitations due to technical difficulties, and has to rely on PDX tumour-
derived cultures (Bruna et al. 2016). 
Tumoroids could represent the tool that would bridge the gap between cancer cell lines 
and PDX models. Until now, it has been impossible to derive and propagate primary 
liver tumour cells in vitro from patients into cultures that maintain tumour identity and 
genetic aberrations. Although cell lines can be aggregated to form spheroid structures 
that more closely mimic a real tumour, they still cannot recapitulate tumour histology 
and genetics. Instead, we have shown that PLC-derived tumoroids have histological 
architecture associated with the tumour of origin. Strikingly, we have managed to 
establish tumoroid cultures not only from HCC, but also from CCs and CHCs, for which 
in vitro model systems are not readily available. It is clear then, that validating this 
system as a reliable cancer model may eventually enhance how tumours are studied 
and treated. In this regard, we have shown that tumoroids retain the same mutational 
profile of the original tumour tissue. This is a key point if the system is to be used to 
test personalised treatment strategies. More importantly, we have shown that knowing 
the mutational profile of tumoroids, can help to predict drug efficiency and sensitivity 
of the cultures. So not only can tumoroids be used to assess which drug is the best 
drug to be used for the subject patient, but the same drug could be used to treat 
patients bearing tumours with a similar mutational profile. However, knowing the 
mutational profile might not always be enough to know which drugs to use. 
Nonetheless, tumoroids can be expanded long-term and can be frozen and thawed 
several times, without affecting their expansion potential. This represents a great 
advantage of this culture system as it could actually be used to virtually test an 
unlimited number of drugs, thus removing the intermediate PDX step. 
One concern that might arise is whether tumoroids maintain the identity of the tumour 
of origin after several passages. We have performed xenograft experiments showing 
that tumoroids cultured for more than 3 months, not only are able to generate tumours 
in vivo, but also retain the same features observed in the tumour of origin. Also, when 
tumoroids derived from a patient with a history of metastatic disease were injected in 
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the kidney capsule, mice developed secondary metastatic nodules in the lung, further 
proving their modelling capabilities. 
Data presented here suggests that tumoroids could become a new attractive model to 
bolster our current arsenal of tools in cancer biology. This could have a monumental 
impact on how liver tumours are currently handled. Tumoroids exhibit the best features 
of both cell line and PDXs models whilst avoiding several of their downfalls.  For 
instance, the expansion potential and ease at which large scale experiments can be 
carried out in cancer cells lines is maintained in tumoroids. However, tumoroids can 
also histologically and genetically mimic the tumour of origin, a key advantage of using 
animal models such as PDXs. More importantly, whilst tumoroids seem to represent 
the best of both worlds they remove some of the limitations that these two systems 
have. For instance, they retain the tumour identity even after long-term expansion, 
unlike cancer cell lines, and can be propagated and expanded indefinitely, not possible 
in PDX models.  
Despite several advantages of using tumoroids, they also have limitations of their own. 
Unfortunately, we were unable to find culture conditions that would allow growth of well 
differentiated HCC (wHCC) samples, restricting the use of our model to tumours with 
a poorly or moderate/well differentiation state. Strikingly, we were able to generate 
tumoroids from all the poorly and moderate/well tumours (100% efficiency) but none 
from the wHCC (0% efficiency) (Annex, Table 9.1). We have observed that the ability 
of establishing tumoroids from PLCs, correlates very well with the proliferative rate of 
the original tissue. In line with this, well differentiated HCCs exhibit a very low number 
of proliferative cells. Possible solutions to this issue could be to enrich for the 
proliferative cells in these tissues when deriving organoid cultures. However, surface 
markers for these tumour proliferative cells have not been identified yet, making this a 
challenging approach.  In addition to this, being an in vitro system, tumoroids still lack 
interaction with the tumour microenvironment. For this reason, validation with animal 
models might still be required, although in lower numbers. Also, at the current stage, 
we are unable to say whether our culture condition favours expansions of some cells 
or clones over the other, thus changing the culture composition over time and resulting 
in a false positive or false negative when performing drug screening. To investigate 
this further, we are currently trying to understand whether tumoroids can also 
recapitulate tumour heterogeneity and whether this feature is maintained after 
derivation of the line and long-term culture. 
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These data prove that tumoroids could be a valid new alternative to cell lines and PDX 
models to faithfully model PLCs in vitro. The expansion potential, the histology and 
genetic features recapitulating the tumour they derive from, make PLC-derived 
tumoroids a powerful new tool that could change the approach to the treatment of this 
disease. 
Current work and future plans 
- Further characterisation of tumoroids lines is currently ongoing or has been 
already performed by Dr. Laura Broutier and this includes: IHC and IF staining 
for cancer subtype specific markers, deeper analysis of expression profile and 
genomic data. 
- In collaboration with the Sanger Institute we have performed a drug screening 
on some of the tumoroids lines to further assess their use as cancer models for 
therapeutic approaches. We have once again observed a correlation between 
drug resistance/sensibility and genetic profile. 
- Interesting drug candidates have been validated in vivo by injecting the drug 
directly in the tumour mass of xenotransplantated mice. Drug efficiency in killing 
the tumour was assessed by comparing with vehicle-injected tumours. 
- We are now currently investigating the heterogeneity potential of the cultures by 
performing single-cell RNAseq at early and late passage and comparing the 
results with data gathered from the original tissue. 
This work has been accepted in Nature Medicine and further data can be found on 
the manuscript once published.   
 
6.2 Genetic engineering of human healthy liver organoids to 
model liver cancer initiation and/or progression in vitro 
When it comes to study the role of specific genes or specific mutations and their 
contribution to cancer formation, animal models have become the gold standard. The 
most common strategy for gene function studies is to either alter (specific mutagenesis) 
or completely remove (knock-out) the gene of interest from the organism or a specific 
tissue. The introduction of the Cre-loxP system has overall facilitated the DNA 
modification of the host genome, and most of gene function studies in cancer research 
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rely on the use of this system (Horie et al. 2004; Nantasanti et al. 2016; Zender et al. 
2013; Saha et al. 2014). From the design of a targeting vector to the generation of a 
conditional mouse model, it can take up to two years before starting any experiment 
and obtaining any information on the gene of interest. With the introduction of the 
CRIPR/Cas9 system, the science community has found other ways that allow for faster 
results. For instance, viral vectors containing gRNAs can directly be injected into mice 
expressing a Cas9 protein, thus eliminating the need of crossing multiple mice lines 
and making it easier to mutate multiple genes at once (Platt et al. 2014). 
In the second section of the results, I have shown how human liver organoids can be 
genetically manipulated to study gene contribution to cancer formation using the 
CRISPR technology. The whole process takes between four to six months, and this 
includes not only the generation of the mutant cultures, but also their analysis. Could 
this system be used as a valid alternative to animal models to study gene functions? 
I have generated TP53-mutated human liver organoids and shown that while the 
mutation introduced was efficiently inactivating the gene, the culture was acquiring 
phenotypical changes reminiscent of malignant transformation. The histologic features 
of the cultures and the aneuploidy observed, all pointed towards TP53 mutations alone 
being already enough to induce cellular transformation. Although TP53 is a well-known 
tumour suppressor gene, it was anyway surprising to observe such changes upon its 
inactivation. In most of the cases, mouse livers do not develop tumours when a single 
gene is mutated and a second hit is usually required. In line with this, when Tp53 is 
mutated in mice, livers do not develop tumours unless further mutations or/and a 
damage are applied (Nantasanti et al. 2016; Dumble et al. 2001). This could represent 
a stark difference in how mouse and human livers respond to specific genes mutations. 
However, it is important to consider the model system used and to try to understand 
whether this difference is real or model system-dependent. Human liver organoids 
originate when ducts are placed in specific media conditions and start proliferating 
(Huch et al. 2014). In vivo, ductal proliferation (ductular reaction) is observed only after 
damage, and ducts are not actively proliferating in homeostasis conditions (Preisegger 
et al. 1999). Thus, taking into account the proliferation status of the culture, liver 
organoids could be considered as a model for damage-induced ductal proliferation. 
This could explain why one single mutation in a tumour suppressor might already 
induce phenotypical changes to organoid cultures that otherwise would not be 
observed in a homeostatic liver. However, to know whether this is true or the phenotype 
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observed is due to mouse-human differences, I have recently established mouse liver 
organoids from tp53 mutant mice and I am currently assessing whether they would 
recapitulate what I have observed in the human system (malignant transformation) or 
they would instead remain normal. 
Considering the positive results obtained from the TP53 mutant model, I sought to 
explore whether the same strategy could be used to screen for genes that have only 
recently been found to have a role in cancer, namely RNF43 and ZNRF3 (R&Z) (Koo 
et al. 2012). Unfortunately, although being resistant to RSPO1 withdrawal and showing 
WNT target genes overexpression, R&Z double mutant clones had limited expansion 
potential, making it difficult to further analyse the effect of their deletion in this model 
system. Only one clone, hR-/-Z-/if-1, has survived so far up to passage 19, suggesting 
that at least one functional copy of ZNRF3 is essential to allow organoids survival. 
However, this experiment needs to be repeated to confirm this result and, RNF43 and 
ZNRF3 single KO are needed to rule out whether the effect observed is ZNRF3-specific 
or whether it applies to RNF43 too. Importantly, when R&Z were mutated together with 
TP53, organoids acquired some of the features observed in tumoroids, including 
aneuploidy, and I have been able to expand the culture beyond passage 15. This data 
suggests that mutations in genes involved in different pathways might be needed to 
better recapitulate a tumour phenotype and might also help in preventing cell growth 
arrest caused by the deregulation of one of the pathway. 
Taking into consideration all the data I have presented in this section, it is hard to 
suggest that using CRISPR/Cas9 system with human liver organoid culture is a valid 
replacement for current animal models and techniques. In order to delve deeper into 
this problem, full characterisation of mutant clones and more examples are needed to 
better understand any potential advantages this system may have. In addition, I have 
encountered a series of technical challenges that has made the system more difficult 
than expected. A key issue that arose from this work is that the transfection efficiency 
of liver organoids is very poor. I have tried several different methods to optimise the 
transfection of plasmids containing Cas9 and gRNAs into organoids. Lipofection using 
lipofectamine 3000 proved to be the best method with up to ~13% efficiency versus 
the ~2% and ~4% on average obtained with lipofectamine 2000 and electroporation 
respectively. However, the use of lipofectamine 3000 has been quite unreliable, with 
the efficiency often dropping as low as ~2%. The second major difficulty I have 
encountered is a potent growth arrest after introduction of the mutations. As 
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mentioned, R&Z KO clones have stopped growing around passage 9, while TP53 and 
TP53+R&Z mutants, although being able to expand longer, suffer from a slower 
expansion rate over time. Whether this is mutation-dependent or due to technical 
issues is still to be established. One potential explanation is that throughout the 
transfection process cells undergo a series of steps that may induce cellular damage 
resulting in a permanent negative impact on their proliferative potential (two steps of 
single cells dissociation, FACS sorting). Finally, we need to consider that, after sorting, 
cells are grown clonally, which means that from one single mutated cell a new organoid 
line is derived. Although these cells come from the same starting culture, liver 
organoids exhibit some intrinsic heterogeneity and, by growing single cells clonally, 
cells with less proliferative potential might be selected, thus resulting in premature 
growth arrest. 
Finally, we need to consider that, as organoids are composed by ductal/progenitor 
cells, they could be used to model CC (cholangiocyte-like tumour) using this system, 
but it might not be possible to model HCC (hepatocyte-like tumour). Deep analysis of 
mutant cultures is needed in order to assess whether specific mutations could drive 
cells towards a hepatocyte-like state and, only then, could be used to model HCC. 
Alternatively, a possible solution would be to induce the differentiation of the organoids 
into hepatocytes after the mutations have been introduced. In this case, if the mutation 
is tumorigenic, it might further push towards a HCC phenotype instead of a CC one.  
It is then clear that, if this system is to be used to study gene function or, more 
specifically, the role of specific genes in cancer, further optimisation of the protocol to 
overcome the above issues is required. By increasing the transfection efficiency, an 
increased number of mutant clones can be generated, thus decreasing the chances of 
selecting less fit cells. If optimization of the protocol is achieved, then we may be able 
to uncover the true power of this system and correctly assess its potential against 
current animal models. 
Future plans 
Due to the difficulties above mentioned we have decided to stop this project until we 
can devise a better strategy for introducing mutation in human liver organoids without 
affecting their expansion potential. 
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6.3 R&Z as regulators of mouse liver homeostasis, metabolism 
and regeneration 
The WNT signalling pathway is not only critical for liver development, but it has also 
been shown to have a key role in controlling liver regeneration and metabolic zonation 
(J. Yang et al. 2014). Liver-specific KO of β-catenin, the WNT pathway effector, results 
in decreased liver to body weight ratio and decreased cellular proliferation both in 
homeostasis and after partial hepatectomy, thus resulting in retarded activation and 
completion of the regenerative process (Tan et al. 2006). In addition, livers lacking β-
catenin exhibit loss of expression of the metabolic genes GS and CYP2E1, showing 
the importance of the WNT signalling in regulating correct metabolic function of the 
liver (Sekine et al. 2006). Conversely, stabilisation of β-catenin results in increased 
proliferation and hepatomegaly without giving rise to cancer (Tan et al. 2005). In line 
with this, removal of a key suppressor of the WNT pathway Apc, also results in 
hepatomegaly and can give rise to HCC after >9 months from deletion (Colnot et al. 
2004). Interestingly, APC has been suggested to be the guardian of liver zonation as 
its deletion induce decrease expression of periportal markers and increase of 
perivenous ones (Benhamouche et al. 2006). More recently, a new study has shown 
how global deletion of R&Z, driven by Rosa26-CreERT, results in increased 
proliferation as well as expansion of the GS and CYP2E1 positive regions after 10 
days, suggesting R&Z as novel regulator of liver zonation and in line with their crucial 
role in regulating the WNT pathway (Planas-Paz et al. 2016). To further understand 
the implication of R&Z deletion in the liver, I have induced deletion either in the biliary 
compartment or in the hepatocytes and performed analysis at different time points 
during homeostasis and after damage. 
R&Z conditional deletion in Sox9 expressing cells (biliary ducts and hybrid periportal 
hepatocytes in the liver) did not result in any significant morphologic or structural 
alteration 40 days after induction of deletion, during homeostasis or after DDC-induced 
damage. Of note, mice fed with a DDC diet for 5 days developed ductular reactions 
and collagen deposition around the portal vein with no significant difference between 
KO and control mice at the time point analysed. As ductular reaction should resolve in 
a wild type setting, analysis at a later time point is needed in order to fully exclude a 
possible effect of R&Z deletion in the ducts. However, according to the data gathered 
so far, there seems to be no involvement of R&Z in regulating ductular reaction after 
acute DDC-induced damage. 
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The second approach to uncover the role of R&Z in the liver was to delete the two 
genes from the hepatocytes using an AlbCreERT2 line. Consistent with the already 
published data on the ablation of R&Z from the whole body, hepatocyte-specific R&Z 
deletion triggered an increase in proliferation and it also affected metabolic zonation 
by increasing the GS positive area around the CV. This abhorrent expression pattern 
of GS and the increased proliferation were maintained 7 months from the point of 
deletion. In agreement with what has been described after Apc KO or β-catenin 
stabilisation, hyperplasia was observed after deletion of R&Z. Interestingly, I observed 
increased expression of genes involved in beta oxidation, ketogenesis and fatty acid 
and cholesterol metabolism after 3 months and this expression pattern correlated with 
human steatosis. This was an interesting result as, how I observed at the later time 
point, R&Z KO in the liver eventually lead to sporadic focal fat accumulation and 
steatohepatic injury. This data suggests that R&Z are novel regulators of fat 
metabolism in the mouse liver.  
Of note, as R&Z deletion causes an increased expression of metabolic genes localised 
around the CV and, considering that the CV is the zone where lipogenesis is localised, 
it is not surprising that the metabolic changes observed would result in fat accumulation 
in these livers. This data is in agreement with a recent paper showing that after 
suppression of the WNT pathway by liver-specific KO of Tcf7l2 (encoding for TCF4, 
transcription factor involved in the WNT signalling) leads to an altered ability of these 
livers to metabolise fat and, as a result, to decreased fat accumulation (Boj et al. 2012). 
Furthermore, Tcf7l2 KO was able also to affect glycogen storage and metabolism when 
mice were maintained on a high-fat diet. Therefore, it would be also interesting 
analysing the effect on gluconeogenesis in R&Z deleted livers, as well as other 
metabolic events localised at the PV.  
I have also observed similar results when mice with hepatocyte-specific deletion of 
R&Z were treated with acute and chronic damage. However, while livers were able to 
recover completely after acute damage, they exhibited extensive alterations following 
chronic damage. For instance, regenerative nodules and mild fibrosis were readily 
observed at several time points after chronic damage. As the WNT pathway is involved 
in regeneration (J. Yang et al. 2014), it is possible that upon R&Z deletion, livers fail to 
regenerate properly. Of note, WNT pathway inactivation caused by removal of β-
catenin results in a slower activation of the regenerative process after partial 
hepatectomy (Tan et al. 2006). Considering this, it would be expected an opposite 
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effect when the WNT pathway is instead activated by R&Z KO. However, chronically 
damaged R&Z deleted livers exhibit a higher extent of damage than the wild type 
littermate controls, suggesting impairment in regeneration after repetitive CCl4 
injections. One hypothesis could be that the liver needs a balanced activation of the 
WNT pathway in order to properly regenerate after damage, thus either an excess or 
a shortage of WNT signal results in improper functioning of the regenerative machinery 
(Figure 6.1b). Furthermore, it is possible that the liver activates different regenerative 
mechanisms based on the kind of damage it experiences, thus different amounts of 
WNT activation might be required. Another possibility is that WNT is required for both 
the activation of the proliferative response to the damage as well as for the 
differentiation of the ‘de novo’ produced hepatocytes (Figure 6.1b). Finally, we need to 
consider how the CCl4 damage works in relation to the phenotype that R&Z deletion 
triggers. Specifically, CCl4 kills the hepatocytes around the CV after being metabolised 
by the cytochrome P450. I have observed that R&Z deletion induces overexpression 
of CV specific genes, including Cyp2E1, encoding for the cytochrome P450 (Annex 
Figure 9.1). It is then possible that, due to more hepatocytes expressing the 
cytochrome, R&Z deleted livers are more susceptible to CCl4-induced damage (Figure 
6.1a). Coupling the altered regeneration with the increased damage, R&Z deleted 
livers exhibit morphological changes otherwise not present in a wild type liver 
(regenerative nodules, mild fibrosis) (Figure 6.1c). 
According to this data, it was clear that hepatocytes, lacking R&Z, were not able to fully 
repopulate the liver with functional new hepatocytes upon chronic damage. 
Interestingly, by allowing further recovery by increasing the time between the damage 
and the end of the experiment, R&Z KO livers did show partial regeneration. This 
regeneration was characterised by a milder phenotype with less GS, less Ki67 and 
less Sirius Red staining compared to an earlier time point. This suggests that although 
the regenerative machinery was not working properly, some regeneration was still 
taking place. For this reason, I have recently started to explore whether other 
regenerative mechanisms were being activated in order to help the regenerative 
process. In line with this, PCK staining, a marker for ductal cells, revealed the presence 
of extensive ductular reaction, with the presence of PCK positive cells far from the PV, 
their normal location (Annex Figure 9.2). Further analysis is needed to prove that this 
ductular reaction is responsible for the partial regeneration. Analysing how many 
hepatocytes have functional R&Z after partial regeneration could easily test this. These 
	-	92	-	
hepatocytes could only arise from cells that avoided the initial deletion, such as ductal 
cells. 
After long-term deletion of R&Z, the metabolic defects observed eventually lead to 
extensive cellular damage, sporadic foci of fat accumulation and steatohepatic injury. 
These features are commonly observed in patients suffering from non-alcoholic fatty 
liver disease (NAFLD). More specifically several cellular pathologies are used to 
diagnose the disease such as, steatosis, lobular inflammation, fibrosis and 
hepatocellular ballooning (Takahashi and Fukusato 2014), all of which are observed in 
R&Z KO livers. Although alterations in the WNT pathway are not usually associated 
with NAFLD, β-catenin is known for regulating many of the processes that lead to the 
establishment of the disease, including glucose and lipid metabolism. Also, I observed 
an increase of WNT related genes in a cohort of patients affected by either steatosis 
or non-alcoholic steatosis (NASH), a type of NAFLD. Thus, alteration of the WNT 
pathway and, in this case, of R&Z, can result in a series of metabolic alterations 
culminating in a NAFLD-like phenotype later in life.  
Importantly, NAFLD and the chronic damage caused by the resulting steatohepatic 
injury and reactive oxygen species, can lead to cirrhosis, fibrosis and eventually to 
cancer (Takahashi and Fukusato 2014). Consistent with this, R&Z deletion also 
resulted in the establishment of early hepatocellular carcinoma (eHCC) after chronic 
damage. Whether these tumours arise as a direct consequence of the deletion in 
response to damage, or due to impaired regenerative mechanisms or steatohepatic 
injury or all of them together is still to be evaluated. Of note, R&Z deletion also resulted 
in focal nodular hyperplasia (FNH), which is a blood vessel response to impaired 
regeneration (J. Nault, Bioulac–Sage, and Zucman–Rossi 2013), further supporting 
the hypothesis of R&Z being important for liver regeneration. Further analysis of these 
lesions is needed in order to fully understand their origin. For example, I have observed 
no expression of R&Z in examples of both eHCC and FNH but, as I do not know 
whether these specific lesions initially express the two genes, it is difficult to say 
whether they originate from R&Z deleted cells or come from other cell populations in 
the liver. To answer this question, I am performing DNA analysis of the lesions and I 
will assess whether they have the deleted R&Z alleles. Also, in situ hybridization of 
deleted and undeleted form R&Z will help answer this question. 
In conclusion, R&Z deletion in the liver triggers hepatomegaly and metabolic alteration 
similar to what observed upon manipulation of the WNT pathway using several other 
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mouse models that have already been described. These metabolic changes lead to 
alterations in fat metabolism and steatohepatic injury similar to what happens in 
NAFLD. When chronic damage is applied, R&Z deleted livers fail to fully activate or 
complete the regenerative mechanism and coupling this with the metabolic damage 
observed, it triggers establishment of lesions such as eHCC and FNH (Figure 6.1). 
Therefore, this work presents a novel role for R&Z in regulating not only liver 
metabolism but also regeneration after CCl4-induced damage. 
Current work and future plans 
- To understand the molecular mechanism underlying the phenotype observed, I 
have recently submitted samples, from all conditions at the different time points, 
for RNA sequencing. Analysis of this data will highlight possible pathways and 
processes involved in the mechanism of impaired regeneration, metabolism and 
cancer observed. 
- To assess whether the results observed after chronic damage are due to the 
specific damage model or are due specifically to the lack of R&Z, I plan in testing 
different damage models. Chronic treatment with DDC diet could be used to 
confirm the results observed, as the cytochrome P450 is also involved in this 
chemical-induce damage. On the other hand, liver regeneration after physical 
injury like partial hepatectomy might provide answer regarding the specific effect 
of the deletion of R&Z, as cytochromes are not reported to be involved in the 
repair process following this kind of damage.  
- To further assess the role or R&Z in regulating lipid metabolism, I aim at treating 
mice with a high-fat diet. In case of unbalanced metabolism, R&Z KO mice are 
expected to accumulate fat at higher rate than WT mice.  
- Treatment of WT and R&Z organoids with free-fatty acids, both before and after 
differentiation, might be used to further corroborate a role for R&Z in lipid 
metabolism. In addition, this could be used as a model for steatosis in vitro, as 
also suggested by Kruitwagen et al. 2017. 
- To test whether R&Z deletion might affect hepatocyte differentiation, I am 
planning of inducing differentiation into hepatocytes of WT and R&Z mutant liver 
organoids. Decreased cytochrome activity, LDL uptake and/or albumin 
secretion, might indicate that R&Z are required for complete maturation of 
hepatocytes and explain the retarded regeneration observed. 
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Figure 6.1. Proposed working model for the response to CD of livers with hepatocyte-specific 
deletion of R&Z. a) Deletion of R&Z drives increased expression of CYP2E1. Hepatocytes expressing 
the enzyme die after metabolising CCl4, thus R&Z deleted livers present a more extensive damage as 
more cells express CYP2E1. b) After CD, livers with wild type copies of R&Z are able to regenerate 
properly. Whereas, when the WNT pathway activation is increased due to R&Z deletion, hepatocytes 
are unable to properly initiate/complete the regenerative process. Also, newly formed hepatocytes fail 
to properly differentiate to become functional hepatocytes. This results in increased proliferation of cells 
to try to recover the damage. c) The increased damage and the improper regeneration and 
differentiation lead to formation of regenerative nodules, collagen deposition, ductular reaction, 
immunological infiltrate and giant hepatocytes. At 7 months, eHCC and FNH arise. It is unclear whether 
these lesions arise from the regenerative nodules observed at 3 months or originate from other cells. 
PV, portal vein; CV, central vein; M, month; C, collagen fibres; RN, regenerative nodule; DR, ductular 
reaction; eHCC, early HCC; FNH, focal nodular hyperplasia.	
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7. METHODS 
7.1 In vivo experiments 
7.1.1 Animals 
All mouse experiments were conducted in accordance with procedures approved by 
the UK Home Office relating to the use of Animals in research (Animals Act 1986). 
Conditional knock-out mice for Rnf43 and Znrf3 were already available in the lab. Mice 
were generated as previously described (Koo et al. 2012). Briefly, exons encoding for 
the ring domain of RNF43 and ZNRF3 were flanked by LoxP sites to drive excision in 
presence of a CRE protein. RZ mice were crossed with either Alb1-CreERT2 (Schuler 
et al. 2004) or Sox9-CreERT2 (Jackson Laboratory JAX - http://jaxmice.jax.org/) to 
drive deletion in hepatocytes and cholangiocytes respectively. All experiments were 
started when mice were 7 weeks old. Primers used for genotyping are listed in Table 
7.1. Immunocompromised NOD/Shi-scid/IL-2Rγnull (NSG) mice (Charles River) were 
used for xenotransplantation experiments. 
Table 7.1. Primers used for genotyping 
Gene Forward primer Reverse primer 
Rnf43 ATTGGCATCGCAATTTTCTAA TCGGTGTTCTTAACTGCTGA 
Znrf3 GCAGTAATAAACAGGTAAAGAGCAAA GCTGGAGAGACCGTTCATAAG 
Cre GCGGTCTGGCAGTAAAAACTATC GTGAAACAGCATTGCTGTCACTT 
Alb1-CreERT2 TATTTTGGGCACAACAGAGTC TTCCGGTTATTCAACTTGCAC 
 
7.1.2 Tamoxifen injections 
Tamoxifen (Sigma-Aldrich) was dissolved in sunflower oil and was injected 200mg/kg 
intraperitoneally according to experimental protocol. Oil only was injected to control 
mice. 
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7.1.3 Damage experiments 
Liver damage experiments were performed using toxic agents administrated IP (CCl4) 
or through diet (DDC). CCl4 (Sigma-Aldrich) was diluted in corn oil and administrated 
1ml/kg one time for acute damage experiments (CCl4 dilution 1:10) or 500ul/kg ten 
times in 6 weeks for chronic damage experiments (CCl4 dilution 1:4). For DDC damage 
experiment, food was removed and replaced with DDC-supplemented diet for a total 
of 5 days after which normal food was restored. Mice weight was constantly monitored 
and measured once per week as a minimum. Mice were sacrificed by either cervical 
dislocation or carbon dioxide overdose. Liver, lungs and other relevant tissues were 
collected on ice and stored in PBS until fixed. Tail tip was collected to confirm 
genotype. 
 
7.1.4 Xenograft 
Xenotransplantation was performed by injecting dissociated organoids either 
subcutaneously or inside the kidney capsule. For subcutaneous graft, 1 million cells 
were injected into both flanks of NSG mice with or without BME2 (7mg/ml). Tumours 
size was measured weekly and mice were culled when the tumour reached limit end-
point (size or necrosis). For kidney capsule graft, 500,000 cells were mixed with BME2 
(7mg/ml) and implanted under the renal capsule of anesthetised NSG mice. These 
mice were then culled at different time point (0.5, 1, 2 and 3 month) by cervical 
dislocation and kidney and lung tissues were harvested to assess the growth and the 
metastatic potential of the grafted cells. 
 
7.1.5 Liver perfusion, hepatocytes collection, macrophages and endothelial 
cells sorting 
Mice were culled by carbon dioxide intoxication and head was removed to allow 
exsanguination. Livers were perfused inserting a small tube through the aorta and 
injecting 10ml of perfusion buffer (0.5mM EGTA in PBS), 10ml of perfusion buffer with 
BSA (Sigma-Aldrich) and 10ml of pre-warmed 0.5mg/ml Collagenase A (Sigma 
Aldrich) solution (HBSS 1x, 5mM CaCl2, 20mM HEPES). After 2 minutes incubation, 
livers were carefully removed, place in STOP solution (HBSS 1x, 5mM CaCl2, 20mM 
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HEPES, 0.5% BSA) and disaggregated using tweezers. Mixture was washed several 
times in STOP solution (50G for 2 minutes) and filtered with a 100µm strainer. Pellet 
containing hepatocytes was resuspended in RLT lysis buffer (Quiagen) and frozen at 
-80°C for RNA extraction. Supernatant was centrifuged again at 300g for 5 minutes to 
collect niche cells. Pellet containing niche cells was divided in two fractions and stained 
either with EpCAM-APC (eBioscience) and CD31-PE-Cy7 (AbCAM) antibodies or 
EpCam-APC and CD11b-PE-Cy7 (BD Bioscience) antibodies. Positive cells were 
sorted using a Flow Sorter MoFlo (Dako Colorado, Inc.), resuspended in RLT lysis 
buffer and stored at -80°C. 
 
7.2 Immunohistochemistry 
7.2.1 Tissue processing 
Tissues were dissected and then fixed overnight in 10% buffered formalin (Sigma-
Aldrich). The following day, tissues were divided in two parts to proceed to paraffin 
(Sigma-Aldrich) or OCT (VMR chemicals) embedding. For paraffin embedding, tissues 
were dehydrated in increasing concentration of ethanol (70%, 95% and 100% for 2h 
each) ending in xylene and then incubated overnight in paraffin. The following day, 
tissues were embedded in paraffin blocks and subsequently sectioned at a thickness 
of 5μm using a microtome. Sections were mounted onto SuperFrost Plus slides 
(ThermoFisher) and incubated from 3 to 12h at 60°C before staining. For OCT 
embedding, tissues were incubated in 30% sucrose PBS at 4°C overnight or until the 
tissue sunk, after which they were embedded in OCT blocks and frozen at -20°C. OCT 
blocks were sectioned at a thickness of 8μm using a Leica CM-3050S cryostat and 
mounted onto SuperFrost Plus slides for immunohistochemical analysis. 
 
7.2.2 Immunohistochemistry of paraffin sections 
After deparaffinising in two changes of xylene 5 minutes each, sections were 
rehydrated in descending grades of ethanol (100% 2x, 95%, 70%) 3-5 minutes each 
ending in water. Antigen retrieval was performed either enzymatically or heat-mediated 
based on primary antibody (see Table 7.2 for details). For enzymatic retrieval, sections 
were incubated 10 minutes at 37°C and 10 minutes at RT with TE buffer containing 
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0.5% Triton X-100 and 1/1000 proteinase K (800U/ml). For heat-mediated antigen 
retrieval, samples were incubated in either citrate buffer (10mM Sodium Citrate, pH 6) 
or Tris-EDTA buffer (10mM Tris base, 1mM EDTA solution, 0.05% Tween 20, pH 9.0), 
heated in a microwave to 95-98°C for 20 minutes and then cooled at RT for 20 minutes. 
After antigen retrieval, samples were blocked and permeabilized for 1.5 hours using 
TBS buffer containing 2% foetal bovine serum (FBS), 1% bovine serum albumin (BSA) 
and 1% or 0.1% of Triton x-100 based on antibody (see Table 7.2 for details). Samples 
were than incubated overnight with primary antibody at antibody-dependent 
concentration (see Table 7.2 for details). The following day, samples were washed in 
TBS and endogenous peroxidases were inactivating incubating 15 minutes in 
methanol containing 3% of hydrogen peroxide. Few drops of Poly-HRP-GAMs/Rb IgG 
(Immunologic) secondary antibody was added directly on the sections and incubated 
for 30 minutes. After washing, signal was developed using Bright Dab substrate kit 
(Immunologic) using manufacturer instruction. Sections were counterstained in 
hematoxylin for 5 minutes, dehydrated in ethanol (70%, 95% and 100% 2x) and in two 
changes of xylene 5 minutes each and finally mounted using xylene-based DPX 
mounting media (ThermoFisher). Slides were analysed using optical microscopy. 
Table 7.2. Antibodies used for immunostaining 
Antigen Triton X-100 Retrieval Concentration Distributor 
GS 0.1% Citrate 1/800 BD 
PCK 0.1% Enzymatic 1/500 DAKO 
Ki67 1% Citrate 1/200 Invitrogen 
CD34 0.1% Citrate or Tris-EDTA 1/250 abcam 
KRT19 - Citrate 1/100 Atlas Antibody 
CYP2E1 0.1% Citrate 1/200 Atlas Antibody 
 
7.2.3 Hematoxylin and eosin staining 
Sections were deparaffinised and hydrated to water as previously and then stained 
with hematoxylin solution (Sigma-Aldrich) for 5 minutes and eosin solution (Sigma-
Aldrich) from 30 seconds to 1 minute. Afterwards, sections were dehydrated to xylene 
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and mounted using xylene-based DPX mounting media (Fisher Scientific). Slides were 
analysed using optical microscopy. 
 
7.2.4 Oil red O staining 
Lipids were staining used oil red O staining kit (Sigma-Aldrich) following manufacturer 
protocol. Briefly, frozen sections were hydrated with water, rinsed with 60% 
isopropanol, stained with freshly prepared Oil Red O working solution for 15 minutes 
and rinsed again with 60% isopropanol. Slides were counterstained in hematoxylin for 
5 minutes, washed and mounted using VectaShield mounting media (Vector lab). 
Slides were analysed using optical microscopy. 
 
7.2.5 Picro-Sirius Red staining 
Fibrosis was assessed staining collagen fibres using Picro-Sirius Red staining kit 
(AbCAM) following manufacturer instruction. Briefly, sections were deparaffinised, 
hydrated to water and stained with Picro-Sirius Red Solution for 60 minutes. Sections 
were rinsed quickly in 2 changes of acetic acid solution and then in absolute alcohol. 
Sections were cleared in two changes of xylene and mounted using xylene-based DPX 
mounting media (Fisher Scientific). Slides were analysed using optical microscopy. 
 
7.3 RNA analysis 
RNA was extracted from tissues, cells or organoid cultures using the RNeasy Mini RNA 
Extraction Kit (QIAGEN) according to the manufacturer’s protocol and reverse-
transcribed with the Moloney Murine Leukemia Virus reverse transcriptase (M-MLVRT) 
(Promega) as follows: 10 minutes at room temperature, 50 minutes at 50°C and 15 
minutes at 70°C. The resulting cDNA was amplified with the iTaq™ Universal SYBR® 
Green Supermix (Bio-Rad) and a desired primer pair on the CFX Connect™ Real-Time 
PCR Detection System (Bio-Rad). The cycling conditions used were: 95°C for 3 
minutes and 39 cycles of 95°C for 10 seconds and 55-60°C for 30 seconds (depending 
on the primer pair), followed by a melting curve (from 55-60°C to 95°C with an increase 
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of 0.5°C per cycle) to ensure amplicon specificity. Gene expression was normalised to 
the expression of the housekeeping gene Hprt. Primers used are listed in Table 7.3. 
Table 7.3. List of primers used for qRT-PCR analysis. 
Gene Forward primer Reverse primer 
mRnf43 CCGTGTGTGCCATCTGTCTA GTGGAGTCTTCTGCCTGGTTC 
mZnrf3 GTACTCATCGGTTCCACAGGA TAGTAGGGTAGGCTGGGATGG 
mAxin2 TGTCCAGCAAAACTCTTC CTTCTCTTGAAGGACCTGA 
mLgr5 TCCAACCTCAGCGTCTTC TGGGAATGTGTGTCAAAG 
mHprt AAGCTTGCTGGTGAAAAGGA TTGCGCTCATCTTAGGCTTT 
mSp5 ACTCACTGCAGGCCTTCCT TCCAAGGGTGGAAAAGTCTG 
mFasn ACAGATGATGACAGGAGATGGAAG GAGGCGTCGAACTTGGAGAG 
mAcadl TGCCCTATATTGCGAATTACG AACACCTTGCTTCCATTGAG 
mAcaa2 CCTCAGTTCTTGTCTGTTCAG AGGTGTGCGGTGATTCTG 
mAcaa1a ATCAGAAATGGGTCTTATG ACATTCTCCGAGGTCATC 
mAcot4 TGCGGTACATGCTTCGACAT TCCACTGAATGCAGAGCCATTG 
mCyp2e1 CCCATCATTATCCCTTAC AGTCAGATCTCGATACAG 
mCyp2c39 CGCTAAAGAGATCACATATTC ATAACTCCAGAAACCAGATG 
mHmgcs2 TGAACGAGTGGATGAGATG AGTCCCTATTTACTGCTGTG 
mAqp9 TTTGGCATTTACTATGACGGACTC GGCACCTGGCACGGATAC 
mSlc17a2 ACAATCCAATCAAGACTCTAAGG TCACCACGACAGGCTTTG 
mCyp7a1 GCTGTGGTAGTGAGCTGTTG GTTGTCCAAAGGAGGTTCACC 
mAkr1b10 CTAGTGCCAAACCAGAGGACC TCCTGTATTCGAGAAGGTGTCA 
mFgf21 GTGTCAAAGCCTCTAGGTTTCTT GGTACACATTGTAACCGTCCTC 
mFads2 TCATCGGACACTATTCGGGAG GGGCCAGCTCACCAATCAG 
hRNF43 AAATTAATGCAGTCCCACCC AAACTCCATCAGCTTCTCAG 
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hZNRF3 CATCGTCAACAAGCAGAAAGTG GGAGACCACGACGAAGAAAG 
hAXIN2 AGCTTACATGAGTAATGGGG AATTCCATCTACACTGCTGTC 
hLGR5 GACTTTAACTGGAGCACAGA AGCTTTATTAGGGATGGCAA 
hHPRT AAGAGCTATTGTAATGACCAGT CAAAGTCTGCATTGTTTTGC 
hTNSFRS19 CAGGTGGCTGGGAAGAACTCTC ACACAGTTTCCAGACCGATCC 
hCDKN1A GACTCTCAGGGTCGAAAACG TAGGGCTTCCTCTTGGAGAA 
hSOX9 GGAAGTCGGTGAAGAACGGG TGTTGGAGATGACGTCGCTG 
hKRT19 GTCATGGCCGAGCAGAAC ACCTCCCGGTTCAATTCTTC 
hCYP3A4 TGTGCCTGAGAACACCAGAG GTGGTGGAAATAGTCCCGTG 
hHNF4α GTACTCCTGCAGATTTAGCC CTGTCCTCATAGCTTGACCT 
hALB CTGCCTGCCTGTTGCCAAAGC GGCAAGGTCCGCCCTGTCATC 
 
7.4 Organoid cultures 
7.4.1 Mouse liver organoids/ducts isolation 
Mouse liver organoids were derived and cultured as previously described (Huch, 
Dorrell, et al. 2013). Livers were collected in PBS and dissociated using a collagenase 
solution (Collagenase type XI 0.012%, dispase 0.012%, FBS 1% in DMEM medium) 
and incubated for 3 to 4 hours at 37°C. Mixture was washed several times and ducts 
were hand-picked, mixed with Matrigel (BD Bioscience) and seeded in a 24 multi-well 
plate. After Matrigel had polymerized, culture medium was added. Culture conditions 
for expansion (EM) were based on AdDMEM/F12 (ThermoFisher) supplemented with 
1% B27 (Invitrogen), 1% N2 (Invitrogen), 1.25mM N-acetylcysteine (Sigma-Aldrich), 
10nM gastrin (Sigma-Aldrich), 50ng/ml mEGF (Peprotech), 5% RSPO1 conditioned 
medium (homemade), 100ng/ml Fgf10 (Peprotech), 10mM nicotinamide (Sigma-
Aldrich) and 50ng/ml HGF (Peprotech). To establish the culture, for the first week 
media was supplemented with 25ng/ml Noggin (Peprotech), 30% Wnt conditioned 
media (homemade) and 10µm Rockinase inhibitor (Y27632, Sigma-Aldrich). Weekly, 
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organoids were removed from the matrigel, mechanically dissociated with a narrowed 
Pasteur pipette, and transferred to fresh matrix in a 1:4 split ratio. 
7.4.2 Human specimens 
Liver tumour biopsies (~1cm3) were obtained from biopsies or resection performed at 
Erasmus Medical Center Rotterdam MEC-2013-143, Cambridge University Hospitals 
NHS Trust REC: 15/LO/0753 (Approval by NRES Committee London – Westminster) 
and The Royal Infirmary Hospital Edinburgh REC: 15/ES/0097. Healthy livers biopsies 
(~1cm3) were obtained during liver transplantation performed at the Erasmus Medical 
Center, Rotterdam MEC-2014-060. All patients provided informed consent and 
samples were procured and studies were conducted under Institutional Review Board 
approval prior to tissue acquisition. Samples were confirmed to be tumour or normal 
based on pathological assessment. The histopathological diagnosis of each case was 
confirmed on routine hematoxylin and eosin stained slides and immunohistochemistry 
and analysed by an independent histopathologist. 
 
7.4.3 Human liver donor and tumour-derived organoids isolation 
Human liver donor organoids were derived using previously described protocol (Huch 
et al. 2014). Human liver biopsies (0.5–1 cm3) were minced and incubated with 
digestion solution (2.5mg/ml collagenase D (Roche) in DMEM (Invitrogen), for 2 to 3h 
at 37°C. The digestion was stopped by adding cold DMEM with 1% FBS and the 
suspension was then filtered through a 100 µm Nylon cell strainer and spun 5 minutes 
at 400g. The pellet was washed in cold AdDMEM/F12 (ThermoFisher) then mixed with 
BME2 (Basement Membrane Extract, Type 2, Pathclear). 10,000-30,000 cells were 
seeded per well in a 24 multi-well plate.  
After BME had solidified, donor samples were cultured in expansion medium (EM) 
based on AdDMEM/F12 (ThermoFisher) supplemented with 1% B27 (Invitrogen), 1% 
N2 (Invitrogen), 1.25mM N-acetylcysteine (Sigma-Aldrich), 10nM gastrin (Sigma-
Aldrich), 50ng/ml hEGF (Peprotech), 10% RSPO1 conditioned medium (homemade), 
100ng/ml Fgf10 (Peprotech), 10mM nicotinamide (Sigma-Aldrich), 25ng/ml HGF 
(Peprotech), 5μM A83.01 (Tocris) and 10μM FSK (Tocris). For the first week medium 
was supplemented with 25ng/ml Noggin (Peprotech), 30% Wnt CM (homemade) and 
10µm Y27632 (Sigma-Aldrich). Same media was also used for establishment of all 
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tumoroid lines. In addition, tumoroids were also seeded in media with decreased 
concentration of RSPO1 (1%), to prevent growth of contaminating normal organoids 
originating from non-tumour tissue. For the establishment of the tumour culture, these 
media were kept the first 2 weeks after isolation then, changed into a classical human 
complete medium. For the establishment of the temporal cultures, Y27632 was kept 
until the first split. Medium was changed twice a week. For tumouroids cultures 
establishment, after 2-3 weeks in culture (depending on the sample) the growing 
structures were visually inspected and, if required, contaminating healthy organoids 
were hand-picked to prevent theses from outgrowing the tumouroids structures. Upon 
attainment of dense culture, passaging was performed by mechanical dissociation into 
small fragments via trituration with a glass Pasteur pipet, and transferred to fresh 
matrix. To prepare frozen stocks, organoid cultures were dissociated and mixed with 
recovery cell culture freezing medium (GIBCO) and frozen following standard 
procedures. When required, the cultures were thawed using standard thawing 
procedures and cultured as described above. For the 3-4 days (organoids) or first 2 
weeks (tumouroids) after thawing, the culture medium was supplemented with Y-
27632 (10μM). Organoid pictures were taken with either a Leica M80 stereoscope and 
Leica MC170 HD camera or with an inverted microscope Leica DMIL and Leica DFC 
450C camera. 
 
7.4.4 CRISPR/Cas9 genome engineering 
Guide RNA (gRNA) were designed using the web tool accessible at crispr.mit.edu. 
Oligonucleotides were ordered from Sigma-Aldrich. Sequence and target region of 
gRNAs used can be found on Table 7.4. gRNAs were cloned either in pSpCas9(BB)-
2A-GFP (PX458, Addgene) or pSpCas9n(BB)-2A-GFP (PX459, Addgene) as 
previously described(Ran, Hsu, Wright, et al. 2013). Briefly, 100µM of top and bottom 
strands were annealed and phosphorylated (T4 PNK, NEB) in a 2720 Thermal Cycler 
(Applied Biosystems) at 37°C for 30 minutes, 95 °C for 5 minutes then ramped down 
to 25°C for 5°C per minute. For cloning into the plasmid, annealed oligonucleotides 
were diluted 1:200 in water and incubated with 100ng plasmid, Tango buffer (Thermo 
fisher), 10mM DTT (Thermo fisher), 10mM ATP (NEB), restriction enzyme BbsI (NEB) 
and T7 ligase (NEB) at 37°C for 5 minutes followed by 21°C for 5 min for 6 cycles. The 
product was then treated with PlasmidSafe exonuclease (Epicentre) to digest any 
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residual linearized DNA. Plasmids were then incubated with 10G competent cells 
(Lucigen) 30 minutes on ice and heat-shocked 45 seconds at 42°C. Transformed cells 
were plated on ampicillin selection plates and incubated overnight at 37°C. The next 
day sample colonies were picked and plasmid DNA isolated using QIAprep spin 
miniprep (Quigen) kit according to the manufacturer’s instructions. Plasmid DNA was 
sequenced to determine that guide RNA had correctly inserted into the plasmid. When 
deemed correct, QIAprep spin midiprep kit (Quigen) was used to extract purified DNA 
for subsequent transfection. 
Table 7.4. Primer containing gRNA sequence used for cloning 
Gene gRNA target + PAM Primer Top Primer Bottom 
RNF43 AGTCCGATGCTGATGTAACCAGG CACCGAGTCCGATGCTGATGTAACC AAACGGTTACATCAGCATCGGACTC 
ZNRF3 GGACTTGTATGAATATGGCTGGG CACCGGACTTGTATGAATATGGCT AAACAGCCATATTCATACAAGTCC 
TP53 TGTAACAGTTCCTGCATGGGTCGG CACCGTGTAACAGTTCCTGCATGGG AAACCCCATGCAGGAACTGTTACAC 
 
7.4.5 Transfection 
Transfection of liver organoids was performed using Lipofectamin 300 reagent 
(Thermo fisher). List of transfection performed and donor used can be found in Table 
7.5. Organoids were expanded for 1 week and then dissociated to single cells after 
incubated with TrypLE Express for 5 minutes at 37°C. A total of 3 wells per transfection 
condition were used. Single cells were washed once, resuspended in 450µl of 
expansion medium supplemented with 25ng/ml Noggin (Peprotech), 30% Wnt CM 
(homemade) and 10 µM Y27632 (Sigma-Aldrich) and seeded in non-attaching 48 
multi-well plate. Transfection mix containing 1.5µl of Lipofectamin, 1µl of P3000 
reagent and 5µg of plasmid in Opti-MEM I Reduced Serum Media (Thermo fisher) were 
added to the cells. Plate was spun at 600g for 1h at 32°C and then incubated 4h at 
37°C. After incubation, cells were mixed with BME2 and seeded in a 24 multi-well plate. 
After 72 hours, cells were dissociated to single cells as before and resuspended in EM. 
Single cells were sorted for GFP fluorescence using a MoFlo cell sorter (Dako 
Colorado, Inc.). GFP positive cells were then seeded at clonal density in BME as 
described above and monitored for organoid formation.  For the first 3 days media was 
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complete medium. Once organoids were formed, these were hand-picked and clonally 
expanded for further characterisation. 
Table 7.5. List of transfections and donor organoids used 
gRNA transfected Donor organoids used 
TP53 Donor 5 
RNF43 + ZNRF3 Donor 3 
TP53 + RNF43 + ZNRF3 Donor 5 
 
7.4.6 Organoids genotyping 
To collect DNA organoids were collected, washed with cold PBS to remove matrigel or 
BME, disrupted by pipetting and incubated at 60C overnight with DirectPCR (Viagen) 
lysis buffer containing 1/100 of Proteinase K 800U/ml (NEB). On the following day, 
samples were spun 5 min at max speed and 1 or 2ul of supernatant containing DNA 
was used for PCR reaction. DNA was stored at 4C. To screen DNA for mutations, 
primers spanning the region of interested were designed using the web tool 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). 
Primers used are listed in Table 7.6. DNA was amplified using GoTaq® G2 DNA 
Polymerase (Promega) using standard protocol. Amplicons were purified using 
QIAquick PCR Purification Kit (Quiagen) and sequence was analysed by Sanger 
sequencing by Beckman Coulter Genomics services. The free web tool TIDE 
(https://tide.nki.nl/) was used to screen for CRISPR/Cas9 mutations. In case of 
presence of different mutated alleles, PCR amplicons were cloned using a pGEM®-T 
Easy Vector Systems (Promega) and transformed into DH5α™ Competent Cells 
(Thermo fisher). Colonies were hand-picked and incubated for 1h at 37°C in 100ul of 
lysogeny broth (LB) medium. 2ul of the bacterial cultures were used in a PCR reaction 
and amplicons were sequenced as previously described. 
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Table 7.6. List of primers used for organoid genotyping 
Gene Primer FWD Primer REV 
RNF43 AGCTAAGTGCAAAATCCAGGTC TTACATTTTGAATGACGCTTCC 
ZNRF3 GATCACCATCACTTACAAGG CATGTCTCTTGGAGGTTACT 
TP53 AGGAAATTTGCGTGTGGAGTAT CACAGGTTAAGAGGTCCCAAAG 
 
7.4.7 Organoid formation efficiency and drug resistance 
For organoid formation efficiency quantification, organoid cultures were dissociated to 
single cells after incubation with TrypLE Express (Thermo fisher) for 5min at 37C. Cell 
were counted using counting chambers and a total of 1000 or 500 cells were seeded 
per well. A total of 3 wells per condition were used. For the first three days, medium 
was supplemented with 25ng/ml Noggin (Peprotech), 30% Wnt CM (homemade) and 
10 µm Y27632 (Sigma-Aldrich), then changed to normal expansion medium. Medium 
was changed every three day and organoid number was counted using optical 
microscopy 1-2 week after seeding. For drug resistance experiment, medium was 
supplemented with either 5µm Nutiln3 (Cayman chemical), 3µm IWP2 (Tocris) or 5µm 
Gefitinib. Control cells were treated with DMSO (Sigma-Aldrich) only. 
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9. ANNEX 
	
 
 
 
Table 9.1. List of tissues from donors and patients used for isolation. 
	
	
Figure 9.1. CYP2E1 immunostaining. Immunostaining of CYP2E1 on R&Z control and deleted livers 
following CD. Liver were collected 3 months after the first tamoxifen injection. Scale bar, 500 µm.	
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Figure 9.2. PCK immunostaining. Immunostaining of PCK on R&Z control and deleted livers following 
CD. Liver were collected 3 and 7 months after the first tamoxifen injection. Scale bar, 100µm. 
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